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ABSTRACT 
The immune system has developed along with the evolution of increasingly complex 
cellular organisms to sustain homeostasis and protect from threats. Cancer, a detrimental 
side effect of increasing organismic complexity, typically sequesters the immune system 
and hijacks its functions for its own prosperity. Cancer immunotherapy aims to harness the 
intrinsic potential of the immune system for the therapeutic benefit of cancer patients.  
The focus of this thesis is to identify and evaluate new immunotherapeutic targets in the 
tumor microenvironment, which can be modulated to restrict tumor growth and metastasis. 
Paper I describes a novel mechanism of interaction between marginal zone macrophages 
(MZMs) and marginal zone B cells (MZBs) in the spleen, which can be modulated by 
antibodies (Abs) to scavenger receptor MARCO on MZMs. This study demonstrates that 
MARCO targeting diminishes antigen (Ag) uptake by MZBs, which results in reduced Ag 
deposition in the splenic follicles. As anti-MARCO Abs can also be found in systemic lupus 
erythematosus (SLE), this interaction may affect subsequent adaptive immune responses to 
both self- and foreign antigen.  
Paper II identifies MARCO as a specific marker for a tumor-promoting macrophage subtype 
in the tumor microenvironment of mammary carcinoma, melanoma and colon carcinoma 
tumor models. Targeting MARCO on tumor-associated macrophages (TAMs) by Abs, 
inhibits tumor growth and metastasis and reprograms TAMs to an anti-tumor phenotype. 
Treatment with anti-MARCO mAbs in combination with checkpoint inhibitor, anti-CTLA-4 
ab, may provide a promising approach for cancer immunotherary with clinical relevance for 
human breast cancer and melanoma.  
Paper III reveals the molecular mechanism through which tumor cells imitate immune cells, 
during epithelial-mesenchymal transition (EMT), prompting their targeted metastasis through 
the lymphatics. This study demonstrates that TGF-β, a known inducer of EMT, regulates the 
chemotactic axis CCR7/CCL21, directing preferential lymphatic dissemination of breast 
cancer cells.  
Paper IV evaluates dendritic cell-derived exosomes in a vaccination approach to re-
activate adaptive anti-tumor responses. This study shows that dendritic cell-derived CD1d 
expressing exosomes loaded with α-Galactosylceramide (α-GalCer) can sensitize NKT 
cells and lead to subsequent activation of B cell and effector T cell responses, restricting 
tumor growth.  
In summary, the work presented in this thesis describes novel targets in the tumor 
microenvironment that can be used in immunotherapeutic approaches to re-activate 
endogenous mechanisms of innate and adaptive immunity against cancer. Additionally, it 
gives new insight into gene regulatory pathways controlling metastatic tumor spread, as 
well as utilizes custom designed biological molecules in anti-tumor vaccination strategies. 
Increasing our understanding of the intricate mechanisms regulating the 
immunosuppressive tumor microenvironment will reveal new knowledge and novel targets 
that can contribute to the design of prospective cancer immunotherapies.  
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1 INTRODUCTION  
1.1 THE IMMUNE SYSTEM 
The immune system is an ensemble of sophisticated sensors and effectors that are in place to 
ensure tissue homeostasis and protect from invasion by infectious pathogens. Threats can be 
detected by a plethora of molecular sensors, which vary depending on the context of the 
threat. Accordingly, these sensors also target different responders with various functional 
activities. The common goal of these immune responses is to restore homeostasis or eliminate 
threats by inducing inflammation. Although infectious pathogens are the most commonly 
considered instigators, inflammation also occurs during tissue injury, cancer, autoimmune 
disease and metabolic deregulation 1.  
The existence of the immune system was observed as early as 430 BC by the Athenian 
Thucydides who described that patients who recovered from the plague were not struck a 
second time or to the same extent by the disease. This observation describes the concept of 
immunity, which refers to the physiological state where an organism exhibits lack of 
susceptibility towards unwanted or noxious agents. The term originates from the Latin 
immunitas, which means “to be exempt from”. References to active immunity date back to 
the early 1700s, when the practice of variolation in the Ottoman Empire (Turkey) was 
reported in the Philosophical Transactions of the Royal Society of London.  
In 1796, Edward Jenner, set up an experiment that would for the first time demonstrate the 
workings of active immunotherapy and what we today refer to as immunological memory by 
showing that exposure to cowpox induced protection to smallpox. In 1884 Robert Koch 
identified pathogens as the underlying cause of infectious diseases postulating the “Germ 
theory”. This would set the basis for what Louis Pasteur in 1891 termed vaccination (fr. latin 
vacca; cow), posthumously crediting Jenner for his contribution and expanding the term to 
include immunizations against various different pathogens. In parallel, great advances were 
made in the field of immunology, such as the discovery by Ilya Metchnikov in 1866 of 
leukocytes (white blood cells) with the capacity to ingest pathogens. He termed this process 
phagocytosis and the cells exerting this function phagocytes, an important component of the 
innate immune system 2. This marked the birth of the branch of cellular immunity and earned 
Metchnikov the Nobel prize in 1908.   
Further efforts to elucidate the mechanisms of induced immunity lead Emil von Behring and 
Shibasaburo Kitasato in 1890 to identify antitoxins, soluble factors in the serum, that were 
able to neutralize bacterial toxins. Antitoxins, later termed antibodies (Abs), could confer 
passive immunity to naïve individuals. Paul Ehrlich was the first to suggest the lock-and-key 
model describing the mechanism of molecular interactions through which Abs bound their 
ligands. Antibodies, together with the complement and antimicrobial peptides, constitute 
humoral immunity. The generation of such pathogen-specific immune responses would later 
be attributed to the adaptive immune system, which is acquired during the lifetime of an 
individual.  
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The above-mentioned discoveries come together to form our current view on the concept of 
immunology. As it is understood today, the immune system is a set of interactive networks 
which have evolved to eliminate potential threats (infection) and restore homeostasis 
(following trauma or cancer), while retaining sufficient tolerance to avoid reactivity to self 
(autoimmunity) or otherwise innocuous agents (allergy). A vital prerequisite for this to occur 
is the ability of the immune system to discriminate “self” from “non-self”. Hence, recognition 
is an important capacity of both the early, innate immune system and the late, specific 
adaptive immune system and holds the key to preserving the balance between immune 
tolerance and immune-mediated elimination.  
Below follows a description the two branches of the immune system, which collaborate to 
orchestrate immune cascades with the aim to restore immunity and homeostasis. Particular 
emphasis will be given to the cells and mechanisms relevant to this thesis.   
1.1.1 Lymphoid organs  
Immune cells arise from the CD34+ hematopoietic stem cell lineage whose developmental 
niche is primarily the bone marrow. The bone marrow, along with the fetal liver and the 
thymus are termed primary lymphoid organs and are sites where immune cells are generated. 
Upon differentiation from common progenitors, the pluripotent hematopoietic stem cells, 
immune cells diverge to different lineages and egress from the bone marrow. In the periphery 
they populate different tissues, as well as secondary lymphoid organs, which function as 
major hubs where immune responses are generated. The secondary lymphoid organs include 
the spleen, lymph nodes, Peyer’s patches, mucosa/gut-associated lymphoid tissue 
(MALT/GALT) and tonsils. Secondary lymphoid organs are dispersed throughout the body 
providing a network for efficient communication, facilitating immune interactions. These 
organs are interconnected by the lymphatic vessels. Some sites, however, are ”protected” 
from possible adverse effects of inflammatory responses and therefore immune cell presence 
is restricted 3. These sites are known as immune privileged and include the central nervous 
system, testis and eyes. These sites are instead guarded by other protective mechanisms, such 
as immunoglobulins (Igs) and complement.  
 The spleen, the largest peripheral lymphoid organ, is an important site where innate immune 
cells migrate to orchestrate adaptive immune responses. The splenic red pulp contains 
macrophages, which are responsible for scavenging aging erythrocytes and uptake of antigen 
(Ag) from the blood. The white pulp is the lymphoid compartment of the spleen, which 
consists of highly organized structures, known as the B cell follicles and the surrounding T 
cell areas, much resembling a lymph node. B cell follicles are the sites where Ag-specific 
adaptive immune responses are initiated. In mice, located between the white and red pulp is 
the marginal sinus, which directly connects the spleen to the circulation and is in strategic 
proximity of the marginal zone (MZ) of the spleen surrounding the follicles. Specialized cells 
populating the marginal zone, the marginal zone macrophages (MZMs), the marginal zone B 
cells (MZBs) and dendritic cells (DCs), surveil the blood entering the marginal sinus and 
capture antigens Ags through pattern recognition receptors (PRRs) 4,5 (Figure 1). MZBs 
  5 
shuttle Ags from the MZ into the follicles for Ag-presentation on follicular dendritic cells 
(FDCs) and activation of adaptive T and B cell responses through germinal center (GC) 
formation. The MZ is a dynamic structure where MZMs and MZBs are interdependent for 
their retention in the MZ and their trafficking to specialized splenic compartments upon Ag 
uptake 6. Similar interactions are observed at other sites of immune surveillance, for example 
between subcapsular macrophages and follicular B cells (FOBs) in the lymph nodes, and 
peritoneal macrophages and B1 B cells in the peritoneal cavity. This common interaction 
between the two cell types suggests an important role for macrophages in regulating antigen 
availability and presentation by B cells, which will be addressed further in Paper I.  
 
 
Figure 1. The marginal zone of the spleen  
Immunofluorescence staining on histological section of a mouse spleen. Green indicates MZM expressing 
MARCO, lining the outer side of the marginal sinus of a B cell follicle, B cells are stained with B220 (blue).  
1.1.2 The innate immune system 
The innate immune system is the body’s primary line of defense. It partly consists of physical 
barriers, such as the skin and mucosal surfaces, and anti-microbial peptides, which act by 
inhibiting pathogens at sites of entry. Additionally, the innate immune system consists of 
cells such as monocytes, macrophages, DCs, neutrophils, eosinophils, basophils and mast 
cells which are of myeloid origin, but also some DCs, natural killer (NK) cells and the 
recently described innate lymphoid cells (ILCs), which are lymphocytes. The innate immune 
system is characterized by rapid and broad responses against threats. The “self” vs. “non-self” 
discriminating ability of the innate immune system lies in the vast array of molecular PRRs. 
Some PRRs of ancestral defense systems (such as Ig-like structures, scavenger receptor 
cystein-rich domains and Toll-like receptors) are preserved through evolution. More 
specifically, the mechanistic basis for the innate immune system’s efficiency depends on the 
recognition of common conserved molecular signatures/structures on pathogens, known as 
pathogen-associated molecular patterns (PAMPs), by PRRs. PRRs discriminate molecular 
patterns signaling altered self, non-self and damage/danger 7. PRRs can be divided into 
membrane bound; such as scavenger receptors (SR), toll-like receptors (TLR) and C-type 
lectin receptors, cytoplasmic; such as NOD-like receptors (NLR) and retinoic acid-inducible 
gene (RIG)-I-like receptors (RLR), and secreted; complement receptors and others 8. Charles 
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Janeway proposed the Infectious non-self theory, whereby the immune system recognizes 
noxious foreign agents through PRRs on antigen presenting cells (APCs). Later, Polly 
Matzinger suggested the revised ‘Danger model’, suggesting that the immune system can 
distinguish between dangerous and innocuous stimuli of either self- or foreign origin 9. 
Similarly to PAMP recognition, PRRs are also capable of recognizing endogenous 
components signaling ‘damage’. These signals are released into the surrounding extracellular 
space, actively secreted or exposed on the surface of dying, stressed or injured cells: these 
include calreticulin (CRT), adenosine triphosphate (ATP) and high mobility group protein 
B1 (HMGB1). They are known as danger-associated molecular patterns (DAMPs) and have 
recently been shown to function as adjuvants (generating “sterile” inflammation) for the 
induction of immune responses during cancer immunotherapy, a concept described as 
immunogenic cell death (ICD) 10. Release of extracellular ATP by apoptotic cells functions as 
a “find me” signal, but ATP can also mediate an array of immunoregulatory responses and is 
thus of particular interest for this thesis. ATP release during ICD can activate the immune 
system, however its catabolite adenosine has the opposite effect, immunosuppression. The 
catabolic activity of ectonucleotidase CD39 is responsible for the reversible conversion of 
ATP to ADP (adenosine diphosphate) and ADP to AMP (adenosine monophosphate), while 
CD73 handles the irreversible conversion of AMP to adenosine 11.  
1.1.3 The adaptive immune system 
The adaptive immune system arose as a prerequisite for survival during the evolution of 
increasingly complex organisms and evolved to fulfill the need for a more specialized line of 
defense. In contrast to innate immune responses, adaptive immune responses are not self-
sufficient. They depend on and are tightly interwoven with components of the innate immune 
system for the orchestration of functional cascades of events that aim to restore homeostasis. 
Another basic difference between the two branches of immunity, is the fact that adaptive 
immune responses are antigen-specific and encompass a memory component to previously 
encountered Ags. The main cellular components of the adaptive immune system are the T 
and B cells, which arise from common lymphoid progenitors in the bone marrow and diverge 
into separate lineages in the periphery. Depending on the type of antigen, different types of 
immune responses are orchestrated by the secretion of different cytokines, leading to the 
mobilization of various subsets of immune effector cells. These processes ultimately induce 
clonal expansion of activated T and B cells, as well as deployment to the site of inflammation 
where they exert various effector functions. Thus, the peripheral lymphoid organs, the spleen 
and the lymph nodes, are the sites where cellular components of the innate immune system 
activate cellular and humoral responses of adaptive immunity. 
1.1.4 Lymphocytes 
The cells of the lymphoid lineage originate from common lymphoid progenitors in the bone 
marrow, which give rise to T cells, γδ T cells, NKT cells, NK cells, innate lymphoid cells 
(ILC), subsets of DCs and B cells. The relevant subsets for this thesis are described below.  
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1.1.4.1 T cells 
T cells are part of the lymphoid hematopoietic lineage. T lymphocyte precursors 
(thymocytes) originate from common lymphoid precursors in the bone marrow, which 
migrate to the thymus where T cell development occurs. Like the innate branch, the 
functionality of the adaptive immune system relies on efficient recognition. Therefore, T cells 
express the T cell receptor (TCR) on their surface, which is generated through complex gene 
rearrangements of the Tcr loci during T cell development in the thymus. The TCR consists of 
one α and one β-chain, it has a single unique antigen-recognition site and binds to antigenic 
peptides in complex with the major histocompatibility complex (MHC) on the surface of 
APCs. Upon engagement of the Ag-specific TCR with its cognate Ag, the cell expressing that 
TCR undergoes extensive proliferation, known as clonal expansion, and part of its progeny 
will go on to mount a directed immune response against the specific target, whether it be an 
infected cell or cancer cell. Other progeny will form a memory compartment that can 
instantly be deployed upon re-encounter of the Ag. Consequently each individual acquires a 
unique repertoire of Ag-specific T cell clones depending on their antigenic encounters.  
More specifically, T cell precursors in the thymus express a functional TCR as well as co-
receptors CD4 and CD8. During the first step, T cells whose TCR will engage self-peptide-
MHC (pMHC) complexes on the cell surface of cortical thymic epithelial cells (cTECs) are 
selected, while absence of this “survival” signal results in death by neglect. This process is 
termed positive selection and ensures the functionality of the selected clones. Selected clones 
undergo a second step, negative selection, during which T cells with a TCR that engages self-
pMHC on the surface of medullary TECs too strongly are eliminated through apoptosis. This 
is known as negative selection and aims to eliminate autoreactive clones. Selection is thus, 
regulated by a certain threshold of activation.  
Thereafter, selected naïve T cells egress from the thymus and populate peripheral lymphoid 
tissues, such as the spleen and lymph nodes. There, induction of adaptive immune responses 
relies on the activation of the innate immune system and antigen presentation. During Ag-
presentation by APCs to naïve T cells in peripheral lymph nodes, three signals are required 
for lymphocyte activation to occur. The first signal is provided by engagement of the TCR 
with the peptide-MHC complex and the second signal is provided by the activated DC in the 
form of co-stimulatory molecules CD80 and CD86. Depending on the context of the immune 
response the DC will provide a third activation signal in the form of soluble mediators, such 
as cytokines, which will polarize T cells to different effector phenotypes. pMHC-I complexes 
are recognized by CD8+ T cells, while pMHC-II complexes are recognized by CD4+ T cells. 
Thus, CD8+ T cells become cytotoxic effectors, while CD4+ T cells polarize into various 
helper populations driven by the up-regulation of different transcription factors depending on 
the inflammatory mediators in the microenvironment (more specifically: cytokines interferon 
γ (IFNγ) and IL-12 drive the expression of transcription factor T-bet which leads to T helper 1 
(Th1) polarization. Similarly, IL-4/GATA-3 drive Th2, IL-6/IL-21/IL-23/RORγT drive Th17 
and TGF-β/Foxp3 drive Treg polarization).  
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1.1.4.2 Natural Killer cells 
NK cells were discovered in 1975 by Rolf Kiessling, Eva Klein and Hans Wigzell at 
Karolinska Institutet 12,13 and Ronald Heberman et al. simultaneously, at the University of 
Pittsburgh 14,15. They are cells of lymphoid origin with the capacity to exert cytotoxic activity 
against virus infected or tumor cells without the need for prior activation. As such, they are 
attractive candidates for cancer immunotherapy 16. They are potent producers of IFNγ and 
have cytotoxic granules containing perforin as well as granzyme B. NK cell recognition and 
binding to self-pMHC complexes on the surface of other cells leads to NK cell inhibition. 
This is mediated by the inhibitory killer cell Ig-like receptors (KIR) in human NK cells and 
by the c-type lectin-like Ly49 family of receptors in mice, and by NKG2A, which is 
conserved between the species. NK cells are educated to recognize a vast repertoire of MHC-
I loaded with self-peptides. However, in the absence of self-pMHC-I recognition, lack of 
inhibitory receptor signaling leads NK cell activation, according to the “missing self 
hypothesis” 17. This can occur e.g. in an MHC-I mismatch transplantation setting or in tumors 
that have down-regulated MHC-I as an immune escape mechanism. NK cells also express 
CD16 (FcγRIIIA/B in humans, FcγRIII in mice), a receptor involved in antibody-dependent 
cellular cytotoxicity (ADCC), and can be activated by binding of the Fc-part of Abs, as well 
as activating receptors such as DNAM1, NKp30, NKp44, NKp46 and NKG2D, whose 
ligands are present on tumor cells and infected cells. Thus, the final fate of NK cell responses 
results from the net balance of activating vs. inhibitory signal input.   
1.1.4.3 Natural Killer T cells 
NKT cells are innate lymphoid cells that share characteristics of both NK cells, such as 
expression of NK1.1 and NKG2D, and T cells as they express a TCR 18. They are a small 
population making up 0.1% of the cells in the human circulation. The TCR of NKT cells is 
restricted to CD1d, an MHC-like presentation molecule which presents lipid and glycolipid 
Ag. Like NK cells, upon activation they secrete perforin and granzymes upon activation but 
they are also potent producers of cytokines. Unlike T cells, their TCR is less variable, only 
consisting restricted α and β chains. There are two types of NKT cells, Type I invariant 
NKT cells (iNKT) that bind the prototypic glycolipid Ag α-galactosylceramide (α-GalCer), 
and Type II diverse NKT cells which bind sulfatide. The study of NKT cells has been 
facilitated by the generation of CD1d-tetrameres loaded with α-GalCer. However, 
deciphering between the actions of the two subpopulations is still complex. There are two 
mouse models that allow the in vivo study of NKT cells. Jα18 knock-out (KO) mice are 
deficient in iNKT cells, while CD1d KO lack both subtypes. Thus the observed differential 
outcomes while comparing immune responses in these two strains has helped shed light 
onto the action of Type II NKT cells. In homeostasis, CD1d presents self-lipids to NKT 
cells. In mice, iNKT cells are classified into two major categories based on the expression 
of CD4 and CD8. The majority are CD4+ and the remaining are CD4-CD8-, and differ in 
their ability to secrete cytokines 19. They have been described to contribute to both pro- and 
anti-inflammatory innate immune responses depending on the cytokine context in their 
activation milieu and the lipid Ag they recognize. According to their function NKT cells 
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can be further classified into NKTH1, NKTH2, NKTH17 and NKTFH cells, and upon 
activation they become rapid producers of various cytokines 20. In response to α-GalCer, 
NKT cells secrete IFNγ, inducing the maturation of DC into APCs by providing co-
stimulation via the CD40-CD40L interaction. This interaction also leads to the release of 
interleukin 12 (IL-12) from activated DC which further propagates CD8+ T cells through 
DC-cross-priming via CD70 21. Notably, many solid tumors express CD1d on their surface 
and the role of NKT cells in tumor immune surveillance is compelling, as suggested by 
their low number and loss of functionality in cancer patients 22. Moreover, iNKT cells have 
been reported to kill tumor-associated macrophages, a major immunosuppressive cell type 
found in tumors (described in 1.2.1), thus contributing to anti-tumor immunity 23. Due to 
this, most studies on iNKT cells in cancer immunotherapy utilize the so far best-
characterized agonist, α-GalCer, which has been widely explored both experimentally and 
recently also in clinical trials as an adjuvant in DC-based vaccine approaches 24,25. 
However, attempts to enhance NKT cell mediated anti-tumor responses by administration 
of soluble α-GalCer have been shown to cause anergy and therefore more controllable 
delivery systems and other agonistic analogues are being explored (see Paper IV) 26,27. 
Examples of such are the co-administration of α-GalCer and tumor-Ag or the adoptive 
transfer of a-GalCer–loaded DCs or exosomes with tumor-Ag, both of which induced 
durable NKT cell cytokine responses 28,29.  
1.1.4.4 B cells 
B cells were discovered by Max Cooper in 1965 as a separate type of lymphocytes than T 
cells 30,3130,3130,31 that develop from common lymphocyte precursors in the bone marrow 29,30. 
In the bone marrow, they transition from pro-B cells, late pro-B cells, large pre-B cells, small 
pre-B cells and immature B cells that egress the bone marrow into the blood stream and 
migrate to peripheral lymphoid organs where they later mature 32. During their development 
in the bone marrow B cells interact with stromal cells and recognize Ags through the highly 
specific B cell receptor (BCR), which is a membrane-bound Ig that arises from the random 
rearrangement of the gene segments of the Ig locus. The BCR consists of two pairs of a heavy 
and a light chain (κ, kappa or λ, lambda) which come together to form two identical antigen-
binding regions that directly bind to antigenic peptides, the complementarity determining 
regions (CDRs) 33. Similar to T cells, the cost of the high specificity of a vast array of BCRs 
is the generation of autoreactive B cell clones. Upon engagement of the BCR with self-Ags, 
B cells are eliminated by apoptosis or undergo editing of the Ag-specificity of their BCR to 
avoid self-reactivity and are then released into the periphery. This gives rise to a wide 
repertoire of receptors specificities (up to 108 different ones), which accommodate a vast 
heterogeneity of Ags. Although central tolerance provides an efficient checkpoint it is not 
infallible, as 4% of immature B cells in the periphery are autoreactive. Several mechanisms, 
collectively known as peripheral tolerance, are put in place to compensate for the escape of 
those autoreactive clones from central selection. These include suppression by Tregs, induction 
of anergy in the absence of co-stimulation or presence of co-inhibition, and immune 
privileged sites.  
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The main innate-like B cell subset is the B1 B cells that populate the peritoneal cavity, the 
MZBs lining the marginal sinus of the spleen and the FOBs, which are found in the follicles 
of the spleen and lymph nodes. FOBs express CXCR5, which is important for their 
retention in the follicles in response to CXCL13. While FOBs recirculate, MZBs are mostly 
regarded as resident in the MZ. MZBs comprise a rather scarce, highly specialized B cell 
subpopulation in the spleen. They localize in close proximity to MZMs and DCs filtering 
the incoming blood for particulate Ags. MZBs are generally identified as B220+ CD21hi 
(complement receptor 2) CD23lo. Additionally they also express CD1d and can thus 
recognize lipid Ags. Like other innate-like cells, they are readily activated and respond with 
rapid induction of IgM production and plasma blast formation. MZBs and MZMs are 
interdependent and this cross talk is important for effective capture and coordinated early 
IgM responses to bacterial Ags 34,35. MZBs are important for the continuous shuttling of 
Ags into the follicles via complement receptors and deposition on the FDCs so that GC 
reactions can give rise to Ag-specific adaptive effector and memory responses 36,37. Ag-
loaded CXCR5-expressing MZBs respond to FDC-produced CXCL13 by migrating into the 
follicle and depositing Ag in the form of immune complexes (IC) on FDCs for subsequent 
activation of FOBs. IC deposition is mediated through the interaction of complement 
receptors CD21 on MZBs and CD35 on FDCs. FOBs bind and internalize Ags through the 
BCR, process it and present it on MHC class II on their surface. The additional activation 
signal is delivered by an activated CD4+ T helper cell which travels to the T/B border of the 
spleen, recognizes the peptide-MHCII complex and engages in a cognate T/B cell interaction. 
This leads to up-regulation of CD40L on T cells, which provides the co-stimulatory signal 
upon binding to CD40 on B cells, licensing B cells to enter the GC reaction and resulting in 
plasma cell formation and antibody production 38. During the GC reaction B cells undergo 
class switch recombination and affinity maturation where B cells with high affinity to the Ag 
are selected. The selected B cells then undergo somatic hypermutation (SHM) where random 
mutation in the CDRs of the BCR further increase its specificity and affinity. A specific 
subtype of T cells, of particular importance for the GC reaction, is the T follicular helper cells 
(Tfh). Tfh initiate the GC response by providing survival, proliferation and differentiation 
signals to FOBs after cognate interaction. They also, secrete cytokines which determine the 
subclass (isotype) of the BCR and generated Abs. The resulting high affinity B cells will then 
differentiate into antibody-producing plasma cells or memory B cells. 
Depending on the type of Ag encountered, different modes of B cell activation can occur. 
Antigen types include: Thymus-dependent (TD), such as TNP-KLH and Thymus-
independent (TI). TD Ag activation involves the B cell receiving CD4+ T cell help in the 
form of co-stimulatory CD40-CD40L interaction, as described above. TI Ag can be further 
subdivided into TI type I or TI type II. TI-I Ag (TLR-ligand polysaccharides and cytosine-
phosphodiester-guanin (CpG)) lead to polyclonal B cell activation through engagement of 
TLR4 on the B cell surface. TI-II Ag are long polysaccharides (e.g. dextran, NP-Ficoll) that 
can simultaneously bind and activate multiple B cells. B cell receptors, B1 B cells and MZBs 
are mostly associated to TI Ag responses 39, while FOB are associated to TD Ag responses. 
MZB cells also highly express the MHC-like molecule CD1d, which is involved in lipid Ag 
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presentation to NKT cells in the splenic MZ and red pulp 40.  
The role of B cells in cancer is disputable, with studies reporting both positive and deleterious 
influence of B cells on anti-tumor immunity. In a melanoma tumor model it was shown that 
B cells were essential for the mediation of CD4+ and CD8+ anti-tumor responses 41. Another 
study describes a mechanism through which B cells drive carcinogenesis through the 
generation of immune complexes that bind FcγR, thus contributing to chronic inflammation 
42. Moreover, B cells secrete anti-inflammatory cytokines, such as IL-10 and TGF, which 
have profound immunosuppressive effect on other tumor-infiltrating immune cells 43. The 
role of B cells in the regulation of macrophages in the tumor microenvironment (TME) is 
described in 1.2.1. 
1.1.5 Myeloid cells 
Myeloid cells originate from common myeloid precursors in the bone marrow, which give 
rise to granulocytes, monocytes, macrophages and DCs. The relevant subsets for this thesis, 
with particular focus on macrophages, are described below.  
1.1.5.1 Granulocytes 
Granulocytes are cells of the myeloid hematopoietic lineage and consist of subsets with 
distinct morphology and function, namely eosinophils, mast cells, basophils and neutrophils; 
which are the most abundant subset in humans, accounting for 70% of all circulating 
leukocytes. Neutrophils are short-lived, rapid responders to inflammatory cues, which 
migrate to sites of inflammation through a process known as chemotaxis. At site, they engulf 
microbial pathogens in phagosomes, which then fuse with intracellular granules containing 
reactive oxygen species (ROS), eliminating the pathogen. Alternatively, granules containing 
antimicrobial enzymes are released into the extracellular space. During their high turn over 
rate, dying neutrophils also have the ability to externalize their nuclear content forming 
neutrophil extracellular traps (NETs) that capture pathogens immobilizing them to be 
engulfed by other phagocytes. Eosinophils, basophils and mast cells perform immune 
responses against extracellular pathogens by engaging IgG and IgE antibodies via their Fc 
receptors. 
1.1.5.2 Dendritic cells 
In 1973, Ralph Steinman and Zanvil Cohn discovered a novel cell type, the DCs, which since 
then have been described to be the fundamental cellular sensors of the immune system and 
the bridge between innate and adaptive immune responses (Nobel prize 2011 for R.S.) 44-46. 
DCs belong to the myeloid lineage, they originate from the bone marrow and develop into 
immature tissue-specific subsets that populate and surveil the periphery for potential invaders 
47. Cytokines fms-like tyrosine kinase three ligand (Flt3L) and granulocyte-monocyte colony 
stimulating factor (GM-CSF) are important for DC differentiation. There are two major 
subsets of DC in mouse, the myeloid DCs (mDCs) and the plasmacytoid DCs (pDCs). mDCs 
(also known as conventional DCs) are subdivided into CD8α+ or CD8α- and originate from 
precursors in the blood, while inflammatory DCs arise from circulating inflammatory 
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monocyte precursors 48. pDCs are potent responders to TLR7 and TLR9 stimuli, such as viral 
RNA and bacterial CpG-ODNs (oligodeoxynucleotides), to which they respond by producing 
type I interferons (IFNα, IFNβ).  
Immature DC are phagocytic cells, which typically express high levels of Ag-presenting 
molecules MHC-I and -II and CD1d, integrin CD11c, intracellular adhesion molecule 1 
(ICAM-1) and low levels of co-stimulatory molecules CD80, CD86 and CD40. Ag-
recognition by PRRs, leads to phagocytic uptake and lysosomal degradation, upon which 
antigenic peptides are loaded on MHC class II molecules from the endoplasmic reticulum and 
transported to the cell surface of the DC for subsequent presentation to naïve T cells 49. This 
process leads to DC maturation, at which point the expression of co-stimulatory molecules is 
up-regulated and IL-12 is secreted to assist T cell activation. Additionally, the expression of 
chemokine receptor CCR7 is up-regulated, which detects chemotactic gradients of CCL19 
and CCL21, and induces DC migration to lymph nodes for Ag-presentation to occur 50. 
CD8α+ DCs are capable of Ag cross-presentation through loading on MHC class I molecules. 
Ag-presentation is mediated through the formation of the pMHC/TCR complex. This induces 
changes in the cell membrane topology and causes the rearrangement of MHC-II, and co-
stimulatory molecules CD80 and CD86 on the DC and of TCR, co-receptors CD4, CD8 and 
co-stimulatory molecule CD28 on the T cell, assembling a unique structure at the DC/T cell 
contact interface, the immunological synapse 51. The immunological synapse potentiates the 
relay of three signals that determine the outcome of the interaction: 1) pMHC/TCR-mediated 
T cell activation (CD4/MHC-II or CD8/MHC-I), 2) CD80/CD28 or CD86/CD28 co-
stimulation and 3) cytokine production.  
Due to their inherent ability to coordinate innate and adaptive responses, DCs or DC-
exosomes are potential tools for therapeutic cancer vaccine approaches aiming to induce 
tumor-specific cytotoxic responses and induction of immunological memory (Paper IV) 52.  
1.1.5.3 Monocytes 
Circulating monocytes in the blood can be classified into two types; the inflammatory and the 
resident monocytes. Inflammatory monocytes originate from the bone marrow and respond to 
inflammatory stimuli by differentiating into macrophages or monocyte-derived DCs (in 
human CD14+CD16-, in mouse CCR2+Ly6ChiCX3CR1low) 53. Resident monocytes, on the 
other hand, are thought to originate from circulating inflammatory monocytes and are 
important for tissue homeostasis and repair (in human CD14+/midCD16+, in mouse CCR2-
Ly6C-CX3CR1hi) 54. They rely on the macrophage-colony stimulating factor (M-CSF) for 
their survival and differentiation. Besides the bone marrow, monocytes also populate the 
spleen and are responsible for local replenishment of tissue-resident macrophages. The spleen 
also constitutes a reservoir of inflammatory monocytes that can be easily mobilized in 
response to soluble mediators and recruited to distal inflammatory sites 55. The release of 
monocytes into the circulation, as well as the recruitment to sites of inflammation, are 
dependent on the chemokine CCL2.  
  13 
1.1.5.4 Macrophages  
Macrophages are tissue-resident cells of the mononuclear phagocyte system with extreme 
functional diversity as is evident by the various highly specialized subpopulations across the 
different anatomical locations of the body. The name macrophages originates from the Greek: 
big eaters, from makros “large” + phagein “eat”, and describes their function as professional 
phagocytes responsible for the uptake and clearance of pathogens and endogenous debris 
through a wide array of PRRs. Recent studies have unveiled a broad spectrum of functions of 
macrophages, which far exceed their phagocytic activity, as indicated by their important role 
in the regulation of tissue homeostasis, inflammation and adaptive immune responses 56.  
Subsets of macrophages 
Until recently, tissue-resident macrophages were regarded as descendants of circulating 
monocytes, which derive from hematopoietic stem cell precursors in the bone marrow. 
However, recent fate-mapping studies have shown that most tissue resident macrophages (in 
the lung, liver, peritoneum, spleen red pulp, bone marrow) originate from precursors in the 
yolk sac or the fetal liver during embryogenesis. These populations are self-maintained 
independently from circulating monocytes in steady state during adulthood 57. 
The spleen is our largest peripheral lymphoid organ and is extensively infiltrated by many 
different highly specialized subsets of tissue-resident macrophages. Depending on their sub-
anatomical localization in the spleen these subsets exert different functions related to Ag 
uptake, recycling and presentation. Red pulp macrophages are derived from the fetal liver and 
are responsible for clearance of aged erythrocytes and recycling of heme 58. White pulp 
macrophages (tingible body macrophages) are responsible for the clearance of B cells 
licensed by FDCs in the GC. The MZ of the spleen is the interface between the blood 
circulation and resident lymphocytes of the spleen. More specifically, as the anatomical 
structure of the MZ provides a site for the blood flow to be filtered for Ags, the macrophages 
guarding the marginal sinus are important for the uptake and clearance of self- and foreign 
Ags59. Another specialized macrophage subset, the metallophilic macrophages (MMs) 
expressing CD169 (sialoadhesin, Siglec-1), lines the inner side of the MZ surrounding the 
follicle. Although the origin of MZMs is unclear, they are dependent on the nuclear liver-X 
receptor α (LXRα) and arise early during development 60. Of particular interest for this thesis 
and more in detail described below, are the MZMs. MMs are important for the initiation of 
humoral responses to TD Ags 61.  
MZMs are characterized by their expression of PPRs, amongst which class A scavenger 
receptors SR-A and the MARCO (macrophage receptor with collagenous structure), as well 
as the C-type lectin SIGN-R1 (specific intercellular adhesion molecule-3-grabbing non-
integrin receptor 1). Due to their strategic localization in the MZ in close proximity to MZBs 
and DCs, they have an important role in bridging innate and adaptive immune responses. 
More specifically, SIGN-R1, an orthologue to human DC-SIGN (dendritic cell specific 
intracellular adhesion molecule-3-grabbing non-integrin), on MZMs binds different 
glycoproteins such as the capsular polysaccharide of Streptococcus pneumonia (S. 
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pneumonia) 62 and polysaccharide dextran 63,64. SR-A and MARCO on MZMs are involved in 
binding and clearance of meningococci 65. SIGN-R1 also enhances the clearance of apoptotic 
cells through complement opsonization and is important for maintaining self-tolerance 66. 
Although expressed on the same cell, SIGN-R1 and MARCO, exhibit opposing regulation, 
with MARCO being up-regulated while SIGN-R1 is down-regulated upon activation 67. After 
bacterial or viral Ag uptake, macrophages in the MZ respond by producing a variety of pro-
inflammatory mediators (Type I interferons, IL-1β and TNFα) that ensure the propagation of 
the immune response. However, the same macrophages play an important role in mediating 
the anti-inflammatory effect of intravenous Ig (IVIG), a widely used treatment for many 
chronic autoimmune diseases. Binding of IVIG to SIGN-R1 leads to engagement of the Fcγ 
receptor IIb (FcγRIIb), a negative regulator of inflammation, which leads to an increased 
activation threshold and thereby suppression of autoimmunity 68. MZMs are important for the 
suppression of innate and adaptive immune responses to apoptotic cells and maintenance of 
peripheral tolerance 69,70. Scavenger receptor MARCO is essential for the uptake, clearance 
and maintenance of tolerance to apoptotic cells 69 and presence of autoantibodies against the 
receptor is indicative of systemic lupus erythematous (SLE) 71,72.  
Similarly to MM, CD169+ macrophages, the subcapsular sinus macrophages in the lymph 
nodes, are strategically located at site that allows immune surveillance and antigen capture 
from the lymph 73. They play an important role in bridging innate and adaptive immunity as 
they have been shown to activate B cells by presenting opsonized Ags 74,75, to cross-present 
apoptotic tumor cells to CD8+ T cells 76 and to present lipid Ags to NKT cells 77. During an 
immune response CD169+ macrophages in the lymph nodes are mobilized into B cell follicles 
and during the GC reaction localize at the T-B border, supporting a role in Ag transport 78. 
Medullary macrophages in the lymph nodes, which are responsible for filtering the lymph for 
particulate Ags, are also known to express CD169, SIGN-R1, SR-A and MARCO.  
Peritoneal macrophages (originating from the fetal liver) are restricted to the transcription 
factor Gata-6 and upon TLR-stimulation with microbial products up-regulate scavenger 
receptor MARCO amongst other PRRs. Due to the easy accessibility peritoneal macrophages 
have been extensively studied both in their naïve state as well as activated upon 
administration of inflammatory agents in the peritoneal cavity.  
Macrophage activation and regulation 
Since macrophage function is highly context dependent, they exhibit great plasticity and 
diversity in phenotype and expression pattern of different molecules 79,80 and are very 
responsive to soluble mediators in their microenvironment. Thus, depending on the micro 
environmental context, macrophages are differently polarized along a continuous spectrum of 
activation states. Reflecting the effect of cytokines IFNγ and IL-4 in inducing Th1 vs. Th2 
immune responses 81, macrophages were classified into classically activated (M1) 82 or 
alternatively activated (M2) 83,84 subsets depending on phenotype and function 85. Later 
studies on macrophage activation performed in mouse strains with known predisposition 
toward either Th1 or Th2 responses, led to the distinction between the M1 and M2 activation 
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states based on phenotypic characteristics 86,87. This classification was further developed to 
include several phenotypic marker and functional characteristics that distinguish the two 
activation states 88-91. However, an increasing amount of data demanded a more informative 
classification based on the basic functions macrophages employ to preserve homeostasis, host 
defense, wound healing and immune regulation. This was further extended to include distinct 
transcriptional pathways regulating the different activation states 92,93. Thus, in recent years, 
the M1/M2 dichotomy, which represents two extremes of a linear activation spectrum was 
replaced by a more correct representation of the polarization status as a continuous spectrum 
where all intermediate activations states can be encountered 94. This is illustrated as a color 
wheel where the basic functions are depicted as primary colors and shared functions are 
represented by many different shades in-between, making up a spectrum of activation states 
that are related to different functions 79 (Figure 2). 
 
Figure 2. The colorful wheel of macrophage polarization   
Macrophages can be polarized to a spectrum of different activation states. This is illustrated as a colorful wheel 
where the main macrophage activation modes are shown in primary colors: classical M1 activation in blue, 
wound-healing M2 in yellow and regulatory M2-like in red. Typically, M1 activation occurs in response to Th1-
type cytokines, like IFN and TNF during infection, while M2 is induced during Th2-responses, by IL-4 and IL-
13, e.g. in responses to parasites. M2 macrophages do not constitute a uniform population, thus intermediate 
colors represent activation states with shared characteristics. M2-like immunoregulatory macrophages are 
induced by immune complexes plus LPS or IL-1β, but also by IL-10, TGF-β and glucocorticoids. Finally, TAMs 
are a heterogeneous group and depending on the TME they can share characteristics of different activation states, 
illustrated here as secondary colors. Adapted from reference #78. 
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M1 (or classically activated) macrophages are considered pro-inflammatory and respond to 
IFNγ and TLR stimulation, such as lipolysaccharide (LPS), or tumor necrosis factor (TNF), 
produced by adaptive immune effector cells by exerting microbicidal and tumoricidal 
activities 95,96. IFNγ, produced by NK, NKT cells or macrophages, activates STAT1 and 
interferon regulatory factors (IRF1 and 8), which up-regulate the transcription of cytokine 
receptor genes (IL-15RA, IL-2RA and IL-6R), cell activation molecules (CD38, CD69 and 
CD97) and cell adhesion molecules (integrins, mucin 1). LPS binds to TLR4 which signals 
through myeloid differentiation primary response gene 88 (MyD88), activating 
transcription factors nuclear factor kappa-light-chain enhancer of activated B cells (NF-κB), 
activator protein 1 (AP-1) and signal transducer and activator of transcription 5 (STAT5) to 
induce the production of pro-inflammatory cytokines, chemokines and Ag presentation 
molecules. They also produce high levels of IL-12 and low levels of IL-10. They contain 
inducible nitric oxide synthase (iNOS), which leads to bacterial or cell lysis and they have 
antigen Ag-presenting capacity as indicated by the expression of high levels of MHC-II and 
co-stimulatory molecule CD86. M1 macrophages are potent producers of chemokines 
CCL2, CXCL9 and CXCL10 97-99 and pro-inflammatory cytokines IL-1β, IL-6, IL-23 and 
TNFα. Lately, GM-CSF (granulocyte macrophage colony-stimulating factor) was added to 
the arsenal of stimuli leading to M1 polarization 100. GM-CSF signaling lead to the 
activation and nuclear translocation of STAT5, IRF5 and NF-κB, which ultimately leads to 
the production of pro-inflammatory cytokines (IL-6, IL-8, G-CSF, M-CSF, TNF and IL-1β) 
and up-regulation of molecules associated with Ag presentation, complement- and 
antibody-mediated phagocytosis and migration, such as CD14, FcγRIA and CD163. Thus, 
M1 macrophages drive a so-called Type I immunity through the secretion of mediators that 
attract Th1 cells, which can be beneficial in the case of tumoricidal or microbicidal activity 
but can also cause tissue damage 101. Therefore, they are considered important mediators of 
host defense but are also common culprits in several autoimmune pathologies (Figure 3).  
On the contrary, M2 (alternatively activated) macrophages can be elicited by a broader 
range of stimuli and have thus been subdivided further. More specifically, M2a 
macrophages typically express the IL-4Rα, which is important for their polarization to M2 
through binding to cytokines IL-4 and IL-13, primarily produced by eosinophils, basophils, 
NKT cells and macrophages, leading to STAT6 activation. M2b macrophages bind immune 
complexes through Fc-receptors expressed on their surface in combination with TLR 
stimulation or IL-1R ligands. Engagement of Fc-receptors recruits tyrosine kinase Syk, 
which activates PI3K (phosphoinositide 3-kinase). M2c macrophages are induced by IL-10, 
TGF-β (both potent anti-inflammatory cytokines) or glucocorticoids. IL-10 is produced by 
macrophages in response to TLR- and glucocorticoid signaling and upon engagement of C-
type lectin receptors SIGN-R1 and Dectin 1. IL-10 receptor triggering by its ligand leads to 
STAT3 activation, driving the expression of Fc-receptors, chemokines CXCL13 and 
CXCL4 as well as PRRs: formyl-peptide receptor (FPR1), TLR1, TLR8 and MARCO 102. 
Tumor-associated macrophages (TAMs) are induced by tumor-derived factors, such as IL-
6, LIF (leukemia inhibitory factor) and MCF (macrophage chemotactic factor), and are hard 
to categorize to one specific M2 category as they vary depending on the TME 97,103,104. M-
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CSF has also been shown to shift macrophages to an M2 polarization. Contrary to M1, M2 
macrophages produce low levels of IL-12 and high levels of IL-10, express Ym1 (Chil3) 
and Fizz1 (Retnlα) and produce Arginase 1 which inhibits T cell proliferation by depleting 
arginine from the microenvironment 105. They promote so called Type 2 immunity which 
supports wound healing and tumor progression. They express low levels of MHC-II and 
promote immunosuppression through production of CCL22, which attracts Tregs 106. They 
also express programed death ligand 1 (PD-L1), which antagonizes activated T cells by 
binding to its receptor programed death 1 (PD-1) on their surface and inducing apoptosis 
107. They are considered anti-inflammatory and pro-tumorigenic.  
 
Figure 3. Receptors and ligands involved in macrophage activation and produced mediators  
The main receptor/ligand pairs responsible for M1 activation are IFNγ/-R, LPS/TL4 and TNF/-R, leading to 
the production of pro-inflammatory cytokines and cytotoxic mediators. M2 activation is induced by signaling 
of IL-4 and IL-13 through IL-4Rα and IL-33 via ST2, inducing anti-inflammatory factors and regulatory 
enzymes. Additional receptor/ligand pairs are involved in intermediary activation states that can be 
encountered depending on the microenvironmental context of activation. 
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Scavenger receptors on macrophages  
Scavenger receptors (SR) are PRRS expressed by phagocytes, with wide ligand specificity 
for both endogenous and foreign molecules. SRs comprise a range of receptors grouped 
together based on their ability to bind polyanionic (negatively charged) ligands 108 or based 
on the fact that they contain a highly conserved version of the Ig domain known as the 
scavenger receptor cystein-rich (SRCR) domain 109. Based on their multi-domain structure 
they have been classified into eight different classes (A-H). Due to the wide range of ligand 
specificity they are involved in both homeostatic regulation as well as in various 
inflammatory disease settings and have been extensively studied in the contexts of infection, 
atherosclerosis and autoimmune disease 110-115 116.  
However, an increasing number of studies report the involvement of different scavenger 
receptors also in cancer 117. For example, Class A scavenger receptor A (SR-A), which is 
closely related to MARCO and is expressed on macrophages, has been implicated to promote 
ovarian and pancreatic cancer 118,119. Moreover, it has been shown to negatively regulate Ag-
specific antitumor immunity by limiting Ag cross-presentation 120. In a separate study, 
targeted depletion of SR-A-expressing leukocytes inhibited peritoneal ovarian tumor 
progression 121. SR-A can signal via the receptor tyrosine kinase (Mertk), which is important 
in the uptake of apoptotic cells 122. Mertk was recently associated to M2 polarization and 
promotion of anti-inflammatory responses in cancer 123. This could be linked to increased 
loads of apoptotic tumor cells in the TME. SR-A deficiency, on the other hand, led to a shift 
in M1 polarization of TAMs and delayed tumor growth in a lymphoma model 124.  
Another member of the scavenger receptor family, CD163, has been associated with an M2 
macrophage phenotype in cancer 125. CD163 correlates to negative prognosis and poor patient 
survival in breast cancer 126,127, adult T cell leukemia/lymphoma 128 and rectal cancer 129. 
The various functions of scavenger receptor MARCO are described in detail below, while 
consequences of its targeting on macrophages through monoclonal antibodies in the context 
of sterile- and cancer-related inflammation are discussed in Paper I and II. 
Scavenger receptor MARCO 
Class A scavenger receptor MARCO was cloned by 
Karl Tryggvasson at Karolinska Institutet in 1995. 
MARCO is a membrane bound receptor, which 
structurally consists of a disulphide-bonded trimer 
with a partly collagenous structure (Figure 4) 130. 
The 210kDa protein is composed of three 
glycosylated subunits and consists of five domains; 
the N-terminal short cytoplasmic domain I, the 
membrane-spanning domain II, and domains III, IV 
and V which are extracellular. Domain III is a 75-
residue spacer domain that separates the 
collagenous domain IV from the plasma membrane. 
Figure 4. Schematic representation of the five   
domains of the MARCO structure.  
The SRCR domain is adapted from the RCSB 
Protein data bank. PDB ID: 2OY3 (reference #132) 
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The collagenous domain contains 270 amino acids forming an overall collagenous structure 
which is only interrupted at a single site and is involved in trimerization 131. The 
interruption by an Ala-Gly-Lys sequence suggests a hinge region in the triple helix of the 
MARCO molecule. The C-terminal end domain V of MARCO contains six cysteine 
residues making up the scavenger receptor SRCR domain and proximally the ligand-
binding domain 132 (Figure 4).  
Although structurally closely related to SR-A, MARCO exhibits different regulation 133. For 
example, both SR-A and MARCO bind CpG-ODNs. However, MARCO-binding leads to an 
activating response in macrophages characterized by TLR9-mediated NO production and IL-
12 secretion, while SR-A-binding lead to negative regulation of IL-12 responses 134.  Also, in 
contrast to SR-A expression, which is inducible but not constitutive, expression of MARCO 
is dependent on TLR4-signaling 135,136. MARCO is constitutively expressed on distinct 
subsets of macrophages restricted to certain tissue compartments. MARCO is expressed on 
the macrophages of the MZ of the spleen (MZM) and medullary regions of the lymph nodes 
130. Its expression on this highly specialized subset of macrophages, located in strategic 
proximity to DCs and B cells in the marginal zone, highlights MARCO as an important 
receptor for the capture and clearance of antigens and apoptotic cells from the blood. Inability 
to clear apoptotic cells from the circulation is associated with increased risk for developing 
SLE 137,138. Also, mice lacking MARCO, have a defective MZ architecture, show impaired 
responses to T cell-independent (T-I) type 2 Ag, produce elevated levels of autoantibodies to 
DNA and develop symptoms of SLE 71,139.  Additionally, autoantibodies to MARCO have 
been found early on in mouse models for SLE before the onset of disease and the receptor is 
down-regulated on MZMs 140. Autoantibodies to MARCO have similarly been found in SLE 
patients however it is unclear whether they are involved in driving the disease 71.  
As for most SR, its ligands are negatively charged polyanionic molecules. More 
specifically, MARCO has been shown to bind low density lipoprotein (LDL) through its 
SRCR domain 141, as well as bacterial agents such as Esherichia coli, Staphylococcus 
aureous 130 and LPS 142, but also un-opsonized particles, such as titanium dioxide (TiO2),  
ferric oxide (Fe2O3), silica (CsiO2) and latex beads 64,143-145.  
The fact that MARCO has a very short intracellular domain suggests that the receptor 
requires a signaling partner to relay its downstream effects. Although little is known about the 
exact mechanism of action and interaction partners it is clear that MARCO has a role in 
modulating inflammatory responses. Several studies have attempted to elucidate this by 
studying its function on macrophages. More specifically, it was shown that cooperation of 
MARCO, TLR2 and CD14 induces macrophage cytokine responses to Mycobacterium 
tuberculosis 146, while MARCO co-operation with TLR2 and nucleotide binding 
oligomerization domain-containing 2 (NOD 2) is important for clearance of Streptococcus 
pneumoniae 147. In alveolar macrophages, uteroglobin-related protein 1 (UGRP1) was 
identified as a ligand for MARCO 148.  Moreover, it has been suggested that MARCO is 
negatively regulated by FcRγ through the recruitment of Src homology region 2 domain-
containing phosphatase 1 (SHP-1) during Esherichia coli binding to FcγRIII, resulting in 
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decreased phagocytosis and enhanced production of TNFα 149. Also, ligand internalization by 
MARCO decreases surface-sensed TLR4 responses, while simultaneously enhancing 
intracellular TLR3, NOD2 and NACHT, LRR and PYD domains-containing protein 3 
(NALP3, inflammasome) 150. Similarly, MARCO has been shown to modulate TLR-induced 
DC activation, possibly providing a bridge between innate and adaptive immunity 151. While 
MARCO is important for the clearance of Pneumococcus pneumoniae infection 152, it has a 
deleterious role mediating uptake of the intracellular parasite Leishmania major 153 and 
suppressing early inflammatory responses to Infuenza A viral infection 154 as well as 
facilitating HSV-1 infection and spread 155. 
Although primarily a MZM receptor, MARCO can be rapidly up-regulated on other 
macrophages and DCs after activation by bacterial products 156,157. LPS binding to TLR4 
leads to up-regulation of both MARCO (and SR-A, in both an MyD88-dependent and 
independent ways, and leads to B cell activation 158. Up-regulation of MARCO expression 
is associated with cytoskeletal rearrangements 159, which induce drastic morphological 
changes to cells, such as the formation of lamellipodia and dendritic-like processes. These 
result in loss of cell adhesion and decreased migration, processes that are necessary for the 
engulfment of particles 160. Another study by Grolleau et al. reported that the inducible up-
regulation of MARCO on DCs after pulsing with tumor cell lysate is associated with 
increased phagocytic capacity 161. Here, targeting MARCO with a monoclonal antibody led 
to enhanced DC motility and anti-tumor activity in a mouse model of melanoma 162. In a 
follow-up study, it is was shown that MARCO deficient tumor-pulsed DCs responded to 
CCL21 with an increased migratory capacity to draining lymph nodes of B16 melanoma 
tumors, leading to improved anti-tumor IFNγ T cell responses 163. Similarly, lack of 
MARCO led to enhanced DC migration to lymph nodes and increased production of pro-
inflammatory mediators in the context of airway inflammation 164.  
Human MARCO was recently identified and found to be highly similar to the mouse 
molecule 165. Studies on MARCO expression in humans show a wider distribution pattern 
of the receptor on several tissue macrophage subsets. However it should be noted that 
expression of the receptor was characterized on samples from septic patients and may 
therefore not be representative of the steady state 166. Although extensively studied in 
infection and autoimmunity, the role of MARCO in cancer still remains poorly understood. 
In the context of cancer, the role of MARCO is so far contradictory, correlating with better 
prognosis in follicular lymphomas 167, but with poor prognosis in human breast cancer 168. 
MARCO has been suggested to be expressed on a subpopulation of macrophages in the 
tumor stroma with immunosuppressive activity, however its role is unknown 169. Paper II 
describes an attempt to shed light on the so far diffuse role of MARCO in cancer. Data 
acquired from other physiological or pathophysiological settings so far pinpoint MARCO 
as an important regulator of responses to both self- and exogenous antigens and systemic 
inflammation 170.  
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1.2 THE IMMUNOSUPPRESSIVE TUMOR MICROENVIRONMENT 
Cancer is a multifactorial disease where a number of mechanisms converge to initiate, 
sustain and promote malignancy. The hallmarks of cancer progression include evasion of 
apoptosis, genome instability and mutation, sustained angiogenesis, limitless replicative 
potential, self-sufficiency in growth signals, insensitivity to growth inhibitors, avoiding 
immune destruction, as well as invasion and metastasis. However, tumor cells do not act 
alone in the processes of tumorigenesis, tumor progression and metastasis. They are rather 
part of a permissive microenvironment established by the concerted actions of different cell 
types and stromal components, such as cancer-associated fibroblasts, pericytes, myeloid 
cells, lymphocytes, endothelial cells and extracellular matrix 171. Recently, tumor-
promoting inflammation was recognized as the 10th hallmark of cancer development 172,173. 
It is generally characterized by the presence of inflammatory cells and mediators (e.g. 
chemokines, cytokines) in the tumor stroma, tissue remodeling, angiogenesis and tissue 
repair. The key cellular players in cancer-related inflammation are the tumor-infiltrating 
leukocytes (TILs); cells of the myeloid lineage exhibiting a great degree of plasticity and 
diversity, such as TAMs and the related myeloid-derived suppressor cells (MDSCs), tumor-
associated neutrophils (TANs), mast cells and eosinophils 98. TILs are present in most 
tumors to varying degrees. Although initially the presence of TILs was considered 
beneficial, accumulating evidence suggested that tumor-derived factors imposed phenotypic 
and functional changes on TILs, which altered them to in fact promote tumorigenesis.  
TAMs, TANs and the related MDSCs, but also T regulatory cells (Tregs) are responsible for 
imposing a generalized immunosuppressive milieu within the tumor stroma 174-176. 
Immunosuppression is achieved through a variety of mechanisms, such as up-regulation of 
cell surface receptors, secretion of cytokines and chemokines, and different enzymatic 
activities.  
Shimon Sakaguchi first identified Tregs as a naturally occurring subset of CD4+ T cells. They 
are characterized as CD4+ CD25hi and rely on the transcription factor FoxP3 for their 
development. Other surface markers that are typically expressed on Tregs include CTLA-4, 
glucocorticoid-induced TNF receptor (GITR) and lymphocyte activation gene-3 (LAG-3). 
Tregs are recruited to tumors through the CCR4/CCL17, CCL22, CCR8/CCL1 and 
CCR6/CCL20 chemokine axes to promote suppress anti-tumor immunity 177. Moreover, 
tumors promote Treg expansion by producing TGF-β. Studies have shown that large numbers 
of Tregs in the tumor, but not in the draining lymph nodes, inversely correlate with survival 
of patients with ovarian carcinoma. Therapeutic approaches targeting Tregs for elimination, 
such as targeting GITR or CD25, have shown promising results heaving immunosuppression 
and unleashing anti-tumor CD8+ T cells 178,179.  
Although less explored than TAMs in the context of cancer, tumor-associated neutrophils 
(TANs) are also important mediators of cancer-related inflammation and tumor progression 
180.  TANs are attracted to the inflammatory TME by chemokines, such as tumor-derived 
CXCL8 and epithelial cell-derived CXCL1, 2 and 3. On site, depending on the local 
cytokine milieu they can be polarized to an N1 anti-tumorigenic phenotype with the ability 
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to kill tumor cells and block metastasis or to an N2 pro-tumorigenic phenotype 181. 
Blockade of TGF-β-signaling inhibits N2 polarization 182. While primarily thought to 
originate from granulocytic bone marrow precursors, they have also been shown to 
accumulate in the spleen of tumor-bearing mice, from where they are later deployed to the 
tumor 183. N2 TANs have a variety of immunomodulatory functions, which can have 
profound implications on anti-tumor immunity. These include but are not limited to, 
induction of a tolerogenic DC phenotype 184, affecting NK cell development 185 as well as B 
cell survival and maturation 186. 
MDSCs are a group of heterogeneous immature myeloid precursors with profound capacity 
to suppress effector T cells responses. Under physiological conditions they are present in very 
few numbers and rapidly differentiate into granulocytes, macrophages and immature DCs. 
Normally they account for 20-30% of all cells in the bone marrow, and 2-4% in the spleen, 
while they are absent from lymph nodes. However, pathological inflammation caused by 
cancer, infection, autoimmune disease or trauma, halts their differentiation and induces 
expansion of the immature cells with immunosuppressive capacity. They are subdivided into 
monocytic (Mo-MDSC) and polymorphonuclear (PMN-MDSC), with distinct functions in 
tumors. Mo-MDSC represent ca 20-30%, while PMN-MDSC are 70-80% of the total 
MDSCs in a tumor. In mice, Mo-MDSCs are characterized as CD11b+Gr-1+Ly6Chigh 
Ly6Glow, while PMN-MDSCs are CD11b+Gr-1+Ly6ClowLy6Ghigh. MDSCs employ various 
mechanisms to impose immunosuppression and these may differ between the periphery and 
the tumor site. The suppressive capacity of PMN-MDSCs is mediated by Arg1, while for 
Mo-MDSC iNOS production is more important 187. They have been shown to produce 
chemokines, such as CCL3, CCL4, and CCL5, to attract CCR5+ Tregs in a mouse melanoma 
model 188. MDSC can also induce the de novo generation of Tregs through production of IL-10 
and TGF-β. 189. In lymphoma MDSCs induced Tregs through Arg1 and Ag presentation 190. 
The importance of heaving immunosuppression to achieve a successful immunotherapeutic 
effect in cancer treatment is becoming more and more apparent.  Therefore, strategies to 
eliminate, block the expansion and recruitment or differentiate MDSCs have become the 
subject of numerous investigations. 
1.2.1 Tumor-associated macrophages  
Already in 1863 Virchow described the presence of infiltrating leukocytes in tumors and 
proposed a link between cancer and inflammation. Indeed, as many as 25% of all cancers 
are thought to arise as a consequence of chronic smouldering inflammation 191-195. TAMs 
are a major component of tumor-promoting inflammation and increased numbers have been 
associated with poor prognosis in a variety of human cancers, and breast cancer in 
particular 127,196. In breast cancer, high infiltration of TAMs has been associated with 
hormone receptor negative status, including triple negative tumors, which is the type of 
breast cancer with the poorest clinical outcome 197-199. However, our understanding of the 
distinct phenotypes of TAMs, their distribution in the tumor stroma and the connection to 
pathological outcome is still limited, thus further investigation is warranted.  
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The origin of TAMs is still disputed and several different sources, known to give rise to 
different macrophage subpopulations with distinct functions have been suggested over the 
years (embryonic yolk sac, bone marrow, spleen). In experimental models of mammary 
carcinoma and lung adenocarcinoma models, most TAM populations found in the tumors 
originated from Ly6C+ circulating monocytic precursors 200. However, there is considerable 
debate regarding the origins of the monocytic precursors, some supporting the idea that they 
originate from the bone marrow and others suggesting that they arise from the extramedullary 
hematopoiesis in the spleen 183 that gives rise to an easily mobilized reservoir of pro-
inflammatory monocytic precursors. However, the contribution of the latter compartment 
seems to be minor 201. Finally, Mo-MDSC and PMN-MDSC are able to differentiate into 
mature myeloid cells; macrophages and neutrophils respectively. However, in cancer they are 
skewed to a pathological phenotype, which can give rise to TAMs or TANs 202,203.  
TAMs are recruited to the inflammatory TME, where they are sequestered by tumor-
derived factors, cytokines and chemokines produced by other inflammatory cells and by 
hypoxia, all together contributing to a pro-tumorigenic inflammatory microenvironment 
204,205. Tumors secrete pro-inflammatory mediators, such as IL-6 and TNF, which contribute 
to the conditioning of the inflammatory TME 195. This induces the production of 
chemokines (CCL2, CCL5, CCL22, CXCL1, CXCL8, CXCL12 and MCP) by various 
immune cell types that will attract macrophages to the inflammatory tumor site and 
promote their production of immunosuppressive cytokines, such as IL-10 and CSF-1, as 
well as up-regulate the expression of scavenger receptors SR-A and CD163 99,119. In 
addition, tumor cell and TAM crosstalk through CCR2 and CX3CR1 further drives tumor 
progression and metastasis 206,207. Moreover, tumor-derived prostaglandin E2 and TGF-β 
promote a distinct M2 TAM phenotype, the major regulator of which is NF-κB, the 
downstream signal transducer of the TLR4-MyD88 signaling pathway 208. This generates a 
self-propagating circle of pro-tumorigenic inflammation 209.  
Tregs in particular, are potent inducers of TAMs as they produce abundant amounts of IL-10, 
which promotes the expression of CD163 and CCL18, suppresses the production of pro-
inflammatory cytokines and expression of MHCII 210. CD4+ Th2 helper cells have been 
implicated in the promotion of M2 TAMs through the production of IL-4 211. Also, it has 
been shown, both in vitro and in vivo that B cells producing IL-10 profoundly affect the 
phenotype of macrophages shifting them to M2 polarization 212,213. Moreover, B cells can 
remotely control macrophages through their production of Abs to tumor-related proteins. 
These Abs form immune complexes, which are taken up by macrophages through Fc-
receptors, resulting in M2 polarization 214. MDSCs, physically interact with TAMs and 
suppress macrophage-derived IL-12 in an IL-10-dependent manner, leading to enhanced 
immunosuppression 215. As a result, TAMs evolve into different specialized subsets with 
distinct functions, that ultimately support tumor growth and progression through various 
mechanisms 119,169,216-218. 
Upon recruitment to the inflammatory TME, TAMs produce factors that support tumor cell 
proliferation, neovascularization and metastasis 219 (Figure 5). They have been found to 
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assist invasion of the primary tumor into the surrounding tissue but also intravasation and 
further dissemination of tumor cells. This molecular polarization is reflected in the 
acquisition of a distinct gene expression signature of M2-like TAMs 220-222. These have an 
anti-inflammatory phenotype; suppressing adaptive immunity (TGF-β, IL-10) 174,200, 
promoting tumor growth (EGF), driving the EMT of invading tumor cells (TGF-β) 223, 
tissue remodeling (MMP, cathepsin proteases) 224 and angiogenesis (VEGF; vascular 
endothelial growth factor). TAMs are primarily of M2-like phenotype, but some can have a 
pro-inflammatory M1-like phenotype, which can elicit potent anti-tumor inflammatory 
responses. As for macrophages, the M1/M2 polarization axis is however a mere 
simplification. In reality, tumors are complex heterogeneous tissues and therefore different 
regions of the tumor may have distinct microenvironments. As a result, the macrophage 
infiltrate may vary greatly with regards to phenotype and function depending on their 
localization. Another level of complexity is added depending on the type of cancer and the 
permissiveness of its microenvironment. Consequently, macrophage plasticity and diversity 
create a dynamic environment which evolves with tumor progression, where specialized 
subpopulations of macrophages support different functions 225. The major functions of the 
different TAM subsets are described below.  
 
Figure 5. Function of TAMs and MDSCs in the immunosuppressive tumor microenvironment  
Heterogeneous tumor cells in the TME produce various factors that promote immunosuppression. For example, 
tumor-derived IL-6, LIF, PGE-2 and CSF1, drive the differentiation of MDSCs to M2 TAMs and the 
polarization of M1 TAMs to M2 TAMs. In turn, MDSCs and M2 TAMs secrete TGF-β and pro-angiogenic 
factors that drive the angiogenesis and migration of metastatic tumor cells. The immunosuppressive phenotype 
of M2 TAMs are further sustained by tumor-derived and autocrine TGF-β and CAF-derived IL-6. MDSCs and 
M2 TAMs produce TGF, driving Tregs expansion and inhibition of CD8+ T cell anti-tumor responses. They also 
typically express the enzymes IDO and Arg1, which have a profound inhibitory effect on CD8+ T cells. 
Moreover, MDSCs and TAMs secrete IL-4, IL-6 and IL-10, which drive Th2 T cell differentiation. CD4+ Th2 
cells augment the anti-inflammatory cytokine IL-10 leading to further M1 to M2 TAM polarization. 
Additionally, tumor-derived chemokine CCL2 attracts inflammatory monocytes to the TME, providing a 
replenishing source of TAM precursors. Altogether, these mechanisms establish an immunosuppressive TME 
and inhibit the production of ROS and pro-inflammatory IL-12 and IFNγ by M1 TAMs, leading to diminished 
cytotoxic activity against the tumor. 
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1.2.1.1 TAMs in chemoresistance and angiogenesis  
In a recent study, DeNardo et al. highlighted the prognostic value of a certain TAM-related 
tumor signature  (high TAM count, high CD4+ T cell count and low CD8+ T cell count) and 
associated that to poor response to chemotherapy in breast cancer patients 226. This could be 
due to chemotherapy-induced CFS1 release by the tumor which leads to macrophage 
recruitment, as has been shown to be the case in mouse mammary tumors, or it could be 
related to the immunosuppressive effect of TAMs on CD8+ T cells. Moreover they found that 
CSF-1-targeting only depleted macrophages in poorly vascularized areas of the tumors. 
Hypoxia, is known to drive the recruitment of angiopoietin 2 receptor (Tie2) -expressing 
macrophages 227,228. Tie2+ macrophages up-regulate transcription factors HIF-1α and -2α, 
which control VEGF-A production and suppress T cell function 229-231. TAMs are known to 
have an angiogenic function, which leads to the formation of poorly perfused leaky vessels 
204,225,232,233. Therefore, the authors speculate that by depleting those macrophages the overall 
tumor vasculature is normalized, allowing for better delivery of the chemotherapeutic agent 
232,234.  
1.2.1.2 TAMs in tumor cell invasion and metastasis  
The process of metastasis involves several steps, during which tumor cells invade the 
surrounding normal tissues and extracellular matrix (ECM), intravasate into the blood or 
lymphatic vessels and travel to distal sites where they extravasate and seed micrometastatic 
niches. Recent studies demonstrate that TAMs originate from circulating inflammatory 
monocytes expressing chemokine receptor CCR2, which respond to tumor-derived CCL2 by 
migrating to the site of tumor inflammation 235. There they differentiate into TAMs lining the 
invasive front of tumor cells and assist many of the afore-mentioned processes through the 
production of a wide array of mediators. It has been shown that colony-stimulating factor 1 
(CSF-1), an important factor not only for macrophage differentiation, but also for promoting 
tumor invasion and metastasis is produced by TAMs, which in turn drives the production of 
the tumor attractant epidermal growth factor (EGF). Additionally, macrophage inhibitory 
factor (MIF) promotes tumor cell invasiveness and trafficking. TAMs also produce platelet-
derived growth factor (PDGF) to support tumor cell proliferation. Moreover, TAMs produce 
matrix-degrading enzymes such as matrix metalloproteases (MMPs), cathepsins and 
proteases, which break down ECM and basement membrane to facilitate the invasion of 
tumor cells into the surrounding normal tissue. The detrimental role of TAMs in tumor 
progression has also been shown in macrophage deficient mice, where metastatic disease 
could be avoided in their absence. Alternatively, metastasis could be abrogated by inducing 
the polarization of M2-like TAMs to an M1-like phenotype. Finally, it has been shown that 
macrophages are important for “conditioning” distal sites for the seeding of micrometastases. 
Thus, targeting M2 TAMs in the TME could limit tumor metastasis (Paper II) 236.  
1.2.1.3 TAMS and inhibition of antitumor immunity  
In order to inhibit T cell mediated anti-tumor immunity, TAMs up-regulate the expression 
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of ligands for the inhibitory receptors programmed cell death protein (PD-1 or B7-H1) and 
cytotoxic T-lymphocyte Ag 4 (CTLA-4), on their surface. Under physiological conditions 
these molecules function as safety switches expressed on activated T effector cells when the 
need to resolve inflammation occurs. Engagement of PD-1 and CTLA-4 through their 
respective ligands (PD-L1/-L2 and CD80/CD86), inhibits effector cells from exerting 
cytotoxic functions through induction of apoptosis. PD-L1 is constitutively expressed on 
immune cells and is up-regulated on TAMs by IL-10 and TNFα 107. In contrast, PD-L2 is 
exclusively expressed on APCs. Its expression on monocytes and macrophages is induced 
by CSF-1, IL-4 and IFNγ 237. Both PD-L1 and PD-L2 are up-regulated by TAMs and 
MDSCs 238,239. Another such molecule that is expressed by TAMs and has a suppressive 
effect on the function of T cells by arresting cell the cycle is B7-H4, which is induced in 
macrophages by IL-6 and IL-10 240. 
Lack of co-stimulation is another mechanism TAMs employ to render T cells non-
responsive. CD86 is constitutively expressed on APCs in low amounts and is up-regulated 
upon activation, while CD80 is expressed only upon APC activation. CD80 and CD86 are 
expressed on M1 TAMs 241-243 but are down-regulated on M2 TAMs as a result of hypoxia 
244 and by their interaction with MDSCs 245. 
As previously mentioned, M2 TAMs are potent producers of IL-10 but have very low levels 
of IL-12, an essential cytokine for CD8+ cytotoxic T cells activation, NK cell tumoricidal 
activity 246 and DC Ag presentation 247 (Figure 5). As a result, in the absence IL-12, the 
TME is skewed towards a pro-tumorigenic Th2 immune response, where IL-10 and TGF-β 
impose generalized immunosuppression. IL-10 leads to the expansion of natural Tregs and in 
combination with TGF-β induces the up-regulation of FoxP3 and the generation of induced 
Tregs, which in turn further suppress CD8+ T cell function 248. TGF-β inhibits CD8+ 
cytotoxic function in vivo 249,250 and Th1/Th2 CD4 functions by interfering with lineage-
determining transcription factors 251,252. Additionally, TAMs secrete chemokine CCL22, 
which recruits CCR4+ Tregs 106 and CCL20 that attracts CCR6+ Tregs 253. TAMs also employ 
the enzymatic activity of arginase (encoded by the Arg1 gene), a hallmark of M2 
polarization in itself, to suppress T cells by depleting L-arginine, which is essential for the 
re-expression of the CD3ζ chain after TCR down-regulation upon activation 254,255.  
An additional mechanism utilized by TAMs is regulation through the enzyme indolamine 
2,3-dioxygenase (IDO). IDO depletes tryptophan from the environment thus leading to cell 
cycle arrest and cessation of T cell proliferation and effector functions 256. Alternatively, 
IDO can be expressed by APCs, which capture and present tumor Ag in draining lymph 
nodes to naïve T cells, leading to tolerization against the tumor 257,258. Additionally, 
tryptophan breakdown by-products, such as kyleneurine, are also cytotoxic to T cells, 
which might also be a reason for inhibition of T cell proliferation. 
1.3 EPITHELIAL-MESENCHYMAL TRANSITION IN TUMOR METASTASIS  
Malignant invasion requires tumor cells to undergo EMT, a process recently shown to be 
assisted by M2 TAMs 259-261. EMT is a biological process during which a polarized 
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epithelial cell loses its apical-basal polarity, loses contact to the basement membrane and 
acquires a mesenchymal phenotype associated with increased migratory, invasive and anti-
apoptotic properties. EMT is absolutely essential for several physiological and 
pathophysiological processes, such as implantation, embryogenesis and organ development 
(Type 1 EMT), tissue regeneration and fibrosis (Type 2 EMT), as well as tumor growth and 
cancer progression (Type 3 EMT). EMT is governed by the activation of a highly preserved 
distinct genetic pattern, including Snail/Slug, Twist, Six1, Cripto, Tgf-b, and Wnt/β-catenin, 
across different species 262.  
In cancer progression, tumor cells undergoing EMT are found at the invasive front of the 
tumor and are thought to drive metastasis through intravasation into blood and lymphatic 
vessels, extravasation and seeding of micrometastases at distal sites, at which point the 
tumor cells revert to a mesenchymal-to-epithelial transition (MET). However, not all cancer 
cells can undergo EMT and of the ones that will, not all will survive to seed distal 
metastases. An interesting conundrum in the case of breast cancer is that, while only a few 
cancer progenitor cells can give rise to metastases, a high genetic diversity is observed in 
metastatic breast cancer cells 263. This discrepancy was explained by the fact that 
heterogeneity in cancer is not the result of random genetic aberrations, but is rather 
orchestrated by the evolutionarily conserved genetic programs that make up EMT 264,265.   
TGF-β has been implicated as a major inducer of EMT in cancer through at least two 
pathways. Of importance for this thesis is the p38 mitogen activated protein kinase 
(MAPK)-mediated autocrine TGF-β-induced EMT, which leads to preferential 
dissemination of tumor cells through the lymphatics in a targeted manner 266. Besides being 
produced by tumor cells, TGF-β can be readily produced by several cell types in the 
inflammatory TME, including TAMs, tumor-associated DCs, MDSCs and Tregs 267 (Figure 
5). As previously mentioned TGF-β is considered a master regulator of the processes 
leading up to the conditioning of the TME and the transitioning of the tumor cells for 
metastatic spread. An EMT permissive TME is similar to a wound unable to heal, 
characterized by increased enzymatic activity, matrix remodeling, inflammation, 
pathological tissue regeneration and scarring 268. The conditioning effect of TGF-β on the 
TME relies on imposing immunosuppression by affecting the recruitment, polarization and 
production of inflammatory mediators by immune cells 269. Tumor-derived TGF-β is known 
to attract and polarize macrophages and neutrophils to M2 and N2 activation states 
respectively. This loop is sustained by the induction of TGF-β production by M2 TAMs. 
TAMs have been pinpointed as the main drivers of tumor progression, as they assist 
invasion from the primary tumor into the surrounding tissue by the use of enzymes that 
specialize in breaking down extracellular matrix (matrix metalloproteases, MMPs), 
suppress anti-tumor immune responses, produce pro-tumorigenic growth factors and 
mediators and promote EMT in a NF-κB-dependent manner 223,270. TGF-β further promotes 
the overall immunosuppressive milieu by shifting recruited CD4+ precursors to Th2 
responses and by inducing the de novo generation of Tregs through the up-regulation of 
FoxP3 271,272. Together, an increasing amount of evidence supports a central role for TAMs 
 28 
in sustaining and promoting TGF-β-driven EMT and facilitating tumor cell metastasis 273. 
During inflammation DCs are capable of migrating to lymph nodes through the lymphatics 
in response to chemotactic gradients of molecular cues in order to initiate immune 
responses 274. In study III we investigate the link between TGF-β-induced tumor cell EMT 
and the acquisition of an immune cell-like phenotype, which directs lymphatic 
dissemination and distal metastasis of tumor cells.  
1.4 CANCER IMMUNOTHERAPY  
The field of cancer immunotherapy was born in 1891, when William Coley, a surgeon at the 
New York Cancer Hospital (currently Memorial-Sloan Kettering Cancer Center), injected 
live or inactivated bacteria in order to mimic the spontaneous regression observed in sarcoma 
patients who had experienced infection by Streptococcus pyogenes 275,276. The theory that 
“Coley’s toxins” activated Metchnikoff’s phagocytes to induce inflammation and kill 
bystander tumor cells was gaining momentum amongst immunologists, albeit not amongst 
clinical oncologists who turned to the more traditional treatments options of surgery, radio- 
and chemotherapy.  
Harnessing but also unleashing the natural resources of the immune system for the benefit of 
cancer patients has long been the goal of vigorous research in the field of cancer 
immunotherapy 277. The design and combination of sophisticated therapeutics, which 
overcome tolerance mechanisms and immunosuppression to induce anti-tumor responses 
incorporating a long-term memory component, is the goal to successful treatment of 
metastatic disease. Passive immunotherapy approaches consisting of Abs or adoptive transfer 
of donor effector T cells rely on the induction of an immediate therapeutic effect without the 
need for prior activation. Active immunotherapy, on the other hand, presents much greater 
challenges.  
Active immunotherapy includes several prerequisites. DCs need to take up tumor-specific Ag 
against which central or peripheral tolerance has not been established. Upon Ag encounter the 
DC would also have to receive a second co-stimulatory signal, which would allow it to 
mature into a professional APC. After maturation DCs migrate to draining lymph nodes 
where they present the tumor-antigenic peptides in order to elicit Ag-specific T effector 
responses. DCs may also induce antibody responses, or activate NK and NKT cells. Finally, 
activated lymphocytes need to exert their function at the tumor site, at which point the 
suppressive inflammatory tumor environment provides a new level of complexity to the 
already daunting challenges. Therefore, attempts to simultaneously activate immune effectors 
and modulate components of the inflammatory TME into a less immunosuppressive state are 
of great importance for successful immunotherapy. 
1.4.1 Immunotherapy using monoclonal antibodies 
In 1975 Milstein and Köhler successfully fused B cells from the spleen of an immunized 
mouse with a myeloma cell line and generated an immortal antibody-producing cell line that 
produced large amounts of mAbs against the specific Ag 278. The discovery of the hybridoma 
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technique was going to revolutionize life science research. To understand the different modes 
of action and potential of mAbs I have included a brief introduction into the basic molecular 
aspects of antibodies and Fc receptors.   
Abs or Igs are divided into five classes based on the sequence of the heavy chain constant 
regions; IgA, IgD, IgE, IgG and IgM. Abs are structurally composed of two identical heavy 
(H) and two identical light (L) chains, which interact through disulfide bonds to form a Y-
shaped molecule. They consist of two functional subunits, the Fab (Fragment, Ag binding) 
domain, which is Ag specific, and the Fc (Fragment, crystallizable) domain, which is 
responsible for mediating effector functions through its interaction with Fc receptors or 
complement. The variable region of the Fab domain contains three hypervariable 
complementarity-determining regions (CDRs), which form the Ag-binding site. The most 
common antibody class used in cancer immunotherapies is the IgG, which can be further 
subdivided into subclasses/isotypes IgG1-IgG4 in humans and IgG1, IgG2a, IgG2b and IgG3 
in mice. These bind different FcRs with varying affinities and specificities. Abs undergo post-
translational modifications during which they are differently glycosylated. This has 
implications for the effector functions mediated by the Fc part as the glycan alters its binding 
affinity to FcRs.  
There are two types of FcRs, type I FcRs are transmembrane glycoproteins of the Ig 
superfamily and include FcγRs, while type II FcR belong to the c-type lectin family and 
include DC-SIGN/SIGN-R1 (CD209) and CD23. Depending on the structural conformation 
of the Fc, Abs show a particular preference for either Type I or Type II FcRs. Of particular 
interest for this thesis are type I FcRs, which will therefore be described in more detail. Upon 
antibody binding, activating FcγRs transduce signals through immunoreceptor tyrosine-based 
activation motifs (ITAMs) and inhibitory FcγRs through immunoreceptor tyrosine-based 
inhibitory motifs (ITIMs). In mice there are three activating Fc receptors, namely FcγRI, 
FcγRIII and FcγRIV and one inhibitory, FcγRIIB. In humans the activating FcγRI (CD64), 
FcγRIIA (CD32A), FcγRIIC (CD32C), FcγRIIIA (CD16A), FcγRIIIB (CD16B) and the 
inhibitory FcγRIIB (CD32B) are present. FcγR are expressed on myeloid cells, such as 
monocytes, macrophages, DCs, basophils and mast cells, which can express both activating 
and inhibitory FcγRs. More specifically, monocytes and macrophages express all FcγRs, 
neutrophils mainly express the inhibitory FcγRIIB and the activating FcγRIII and FcγRIV, 
while DCs express FcγRI, FcγRIIB and FcγRRIII. In the lymphoid lineage, NK cells, express 
only the activating receptor FcγRIII, whereas B cells only express the inhibitory receptor 
FcγRIIB. Studies on the therapeutic effects and the mechanisms of action of Abs have 
become more informative after the development of a mouse model in which murine FcRs 
have been replaced by their human counterparts, faithfully recapitulating the human FcR-
expression profile on hematopoietic cells 279. Ab-mediated inflammatory signaling through 
FcRs has been implicated in the physiological processes of Ag presentation and B cell 
selection, but also in the pathophysiological contexts of infection, autoimmune disease, and 
cancer. Growing understanding of the underlying mechanisms governing these responses has 
led to advances in the generation of antibody therapeutics, such as the optimization of Ab Fc-
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design, the customized targeting to particular FcR and enhancement of the binding affinity of 
Abs by introduction of Fc modification, in order to modulate antibody effector functions to 
clinical benefit. Such approaches have been utilized in vaccinations against infectious 
diseases and the development of cytotoxic or immunomodulatory Abs for the treatment of 
autoimmune and neoplastic diseases 280.  
1.4.1.1 Monoclonal antibody therapeutics for cancer  
The use of monoclonal antibodies in cancer therapy can be direct, targeting molecules 
expressed by the tumor itself known as tumor Ags, blocking signaling cascades that are 
important for tumor survival and progression, inducing apoptosis or immunogenic cell death 
281. Tumors have, however, evolved to overcome such blockades, for example by down-
regulating the expression of the targeted tumor-associated Ags (TAA) or selecting clones 
lacking TAA expression 282. Thus, the need for immunomodulatory Abs targeting the 
immunosuppressive TME, aiming to evoke long-lasting anti-tumor immune responses 
emerged. These approaches aim to bridge innate and adaptive effector mechanisms and to 
establish immunological memory against the tumor 283.  
These complex processes boil down to the following basic modes of action for Ab 
therapeutics used in anti-cancer therapies: i) Abs that recognize TAA and target tumor cells 
for elimination by Ab-dependent cellular cytotoxicity (ADCC) or Ab-dependent cellular 
phagocytosis (ADCP), ii) Abs stimulating receptor activity, inducing downstream signaling 
of receptors expressed on the surface of tumor cells or accessory cells in the TME, iii) Abs 
blocking receptor signaling, iv) agonistic immunomodulatory Abs targeting activation 
molecules on immune effector cells to induce anti-tumor responses, and v) antagonistic 
immunomodulatory Abs blocking inhibitory pathways in order to unleash anti-tumor immune 
responses. The last are known as checkpoint immunotherapies and have received immense 
recognition for their therapeutic effects, revolutionizing the field of cancer immunotherapy.  
Antibody-dependent cellular cytotoxicity/-phagocytosis 
One of the main functions of immunotherapeutic Abs is to exert cytotoxic or phagocytic 
activity by engaging secondary immune effector mechanisms. This is mediated through 
ADCC or ADCP, processes during which Abs bound to their ligands interact with activating 
FcR on innate immune effector cells (most commonly NK cells, eosinophils, monocytes and 
macrophages) to mediate target cell lysis or engulfment. The cytotoxic capacity of Abs 
depends on the isotype, which dictates the specificity for different activating FcR 284,285. More 
specifically, mouse IgG2a preferentially binds FcγRI with high affinity, FcγRIV with 
intermediate affinity and FcγRIII with low affinity, while IgG2b binds FcγRIII and FcγRIV. 
In contrast, IgG1 binds inhibitory FcγRIIb with high affinity and to a lesser extent FcγRIII 
and thus has low/no cytotoxic activity 286. Thus, IgG2a and IgG2b isotypes have higher 
cytotoxic potency than IgG1 and IgG3. A recent promising development in the field of 
immunotherapeutic approaches utilizing mAb is the engineering of the Fc part of mAbs to 
enhance or alter their binding affinity or specificity to different FcR and in this way affect 
their mode of action. ADCC is one of the main modes of action of mAbs in cancer 
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immunotherapy the efficacy of which can be improved. Enhancement of ADCC could be 
achieved through the introduction of modifications in the Fc part of mAbs, which lead to 
increased binding affinity to FcRγIIIA 287. In fact in vivo studies in FcR deficient mice have 
highlighted the importance of specific Fc-FcR interactions in mediating the anti-tumor effect 
288-290. Moreover, a recent study in FcγR-humanized showed that while FcγRIIIA-binding on 
macrophages is essential for the ADCC activity of human IgG1 Abs, binding to FcγRIIA on 
DCs is responsible for the induction of a potent vaccinal effect against the tumor 291. 
Moreover, FcR alleles attributing increased binding affinity to activating FcR result in 
increased ADCC and directly correlate with enhanced clinical responses to mAb therapy in 
patients 292-296. There are currently several mAb targeting tumor-associated cell surface 
differentiation Ag, growth factors or molecules involved in angiogenesis that have been 
approved for clinical use in the treatment of cancer. These targets are: ERBB2 (trastuzumab), 
EGFR (cetuximab, panitumumab), VEGF (bevacizumab), CD20 (rituximab, ofatumumab, 
ibritumomab, tositumomab), CD30 (brentuximab), CD33 (gemtuzumab) and CD52 
(alemtuzumab). The anti-CD20 mAb (Rituximab) targets B cells causing their depletion 
through an FcR-dependent manner. Besides being a useful tactic to eliminate malignant B 
cells, this mAb can also be used to deplete B cells in tumor settings where they exert a tumor-
promoting effect, as has been shown in pancreatic cancer 297 
Immunomodulatory antibodies  
Immunomodulatory Abs can target activating molecules on the surface of immune cells. 
CD40, a member of the tumor necrosis factor receptor (TNFR) family, is a co-stimulatory 
molecule, which is expressed on APCs such as DCs, B cells, monocytes and macrophages 298. 
CD40 triggering by the anti-CD40 mAb Dacetuzumab leads to up-regulation of co-
stimulatory molecules, induces cytokine production and enhances Ag presentation. 
Particularly in B cells, it promotes maturation, GC formation, Ig-isotype switching and 
affinity maturation. Its mode of action depends on the inhibitory FcγRIIb, and is similar for 
other members of the TNFR family such as CD95, DR4 (TNFRSF10A) and DR5 
(TNFRSF10B) 299,300. DR3 (TNFRSF25) is expressed on activated CD8+ T cells and interacts 
with TL1A, a TNF-like cytokine, on CD4+ T cells to promote inflammation and NK cell 
activation. Crosslinking of DR3 leads to enhanced cytotoxic NK cell activity. Another 
member of the TNFR family, CD27, is a co-stimulatory molecule expressed on T, B and NK 
cells. Binding of CD27 to its ligand CD70 is important for the effector functions of these 
cells. Crosslinking of the receptor by mAb leads to enhanced immune effector functions. 
Another target receptor is CD137 (4-1BB), which is expressed on activated T cells, Tregs, NK 
cells, NKT cells, DCs, neutrophils and monocytes. Crosslinking of CD137 promotes 
expansion of T cell populations, CD8+ T cell survival, NK cell proliferation and IFNγ 
production 301. Also, targeting activated T cells through their IL-2Rα chain by the anti-CD25 
mAb (Daclizuman), promotes T cell proliferation. Moreover, CD25 is highly expressed by 
Tregs which leads to their transient depletion, leading to increased numbers of effector T cells 
and decreased immunosuppression178.  
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A particular sub-category of immunotherapeutic Abs, known as immune checkpoint 
therapies, has shown great promise, evoking durable clinical responses, in patients with 
metastatic disease, and has revolutionized the field of cancer immunotherapy in the last 
decade. Checkpoint inhibitors aim to block regulatory pathways in T cells that inhibit anti-
tumor responses leading to enhanced co-stimulation 302. The first checkpoint therapeutic to be 
approved by the FDA in 2011 for the treatment of metastatic melanoma was anti-CTLA-4 
(cytotoxic T lymphocyte antigen 4) mAb, Ipilimumab. Ipilimumab targets CTLA-4, a 
negative regulator of T cell activation, which is up-regulated on activated T cells and 
functions a safety switch to attenuate the response. CTLA-4 is a homologue of CD28 and 
binds the same ligands, CD80 and CD86, with much higher affinity. Contrary to the co-
stimulatory effect of CD28, CTLA-4 cross-linking to its ligands leads to inhibition of the 
proliferation of activated T cells 303,304. Validation of the mechanism of action of Abs 
blocking the interaction between CTLA-4 and CD80 was performed in numerous 
experimental settings, in combination with various treatments that would expose TAA and 
make them readily available for uptake by APCs 305-308. Antibody-mediated blocking of 
CTLA-4-mediated suppression unleashed effector T cell activation in an FcR-independent 
manner. At the same time, it induced FcR-dependent elimination of Tregs by intratumoral 
macrophages 309,310.  
Two other immune checkpoint Abs were recently approved by the FDA in 2014. The anti-
PD-1 mAb Pembrolizumab and Nivolumab target programmed death receptor 1 (PD-1), 
which is expressed on activated T cells and B cells and provides a potent inhibitory signal 
when bound to its ligands PD-L1 and PD-L2 expressed on APCs or tumor cells 311. Blocking 
this interaction with mAb interferes with signaling through the TCR leading to T cell 
inactivation 312.  
The ligand for PD-1, PD-L1, can be up-regulated on tumor cells as an immune escape 
mechanism by inducing T cell death. Targeting PD-L1 with mAb inhibits binding to PD-1 
and CD80, rescuing effector T cells. Clinical trials using Ipilimumab and 
Pembrolizumab/Nivolumab or anti-PD-L1 as a combination therapy are on-going and hold 
great promise.  
There are several inhibitory receptors on lymphocytes that have been explored as potential 
targets for Ab-mediated immunotherapy. For instance, OX40 a negative regulator of 
lymphocyte proliferation and cytokine production on activated lymphocytes, GITR, and 
KIR2DL1/L2/L3 and KIR2DS1/S2) on NK cells which inhibit NK cytotoxic activity 313-316. 
New members of the immune checkpoints family are continuously emerging and are being 
evaluated as monotherapies and in combination with already established therapies. These aim 
to provide a blockade of inhibitory pathways, such as LAG-3, VISTA, BTLA and co-
stimulation of activating pathways ICOS 317-322. 
1.4.2 Targeting tumor-associated macrophages  
Modulation of the immunosuppressive myeloid compartment has become a crucial factor in 
determining the success of cancer immunotherapy and is currently the subject of vigorous 
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investigation. Intensive efforts continue to identify candidate molecules targeting different 
aspects of the development and function of TAMs. These have three main goals: 1) to 
decrease the number of precursors recruited to the tumors by inducing apoptosis or 
maturation or by inhibiting their trafficking, 2) to block molecular mechanisms employed by 
TAMs to inhibit lymphocyte tumoricidal activity, and 3) to eliminate TAMs or re-program 
them to an M1 phenotype. The last category is of particular interest for this thesis and some 
examples are mentioned below.  
In a mammary carcinoma model, blockade of the CCL2/CCR2 axis lead to decreased 
recruitment of inflammatory monocytes and macrophages and as a result inhibited metastatic 
spread 323. Combinatorial treatment with clodronate-liposomes and VEGF-neutralizing Abs 
decreased certain TAM subpopulations and led to a reduction in tumor-associated DC and 
blood vessel density 324. Targeting legumain, a stress protein and a member of the asparaginyl 
endopeptidase family, on TAMs, lead to CD8+ cytotoxic T cell responses against TAMs and 
decreased pro-angiogenic factors, such as TGF-β, TNFα, MMP-9 and VEGF, thus 
constricting angiogenesis and metastasis of breast carcinomas 325. Adenoviral delivery of 
CCL16, TLR9 stimulation with CpG DNA and anti-IL-10R Abs led to TAM reprogramming 
from M2 to M1 phenotype leading to tumor de-bulking, followed by DC migration to 
draining lymph nodes for priming of adaptive responses 326. Treatment with soluble IL-12 led 
to a phenotypic switch to M1 TAMs, characterized by a reduction in the levels of anti-
inflammatory IL-10, TGF-β and CCL2 and increased levels of TNF, IL-15 and IL-18, and 
concomitant NK and T cytotoxic cell activation in melanoma, lung and colon carcinoma 327. 
Similarly, adoptive transfer of tumor-specific cytotoxic T cells (CTLs) or chimeric-Ag 
receptor T cells both engineered to release IL-12 shifted the TAM polarization to M1 328,329. 
Targeting of NF-κB, the master regulator of the immunosuppressive phenotype of TAMs, 
through its downstream signaling kinase IκB re-educated TAMs to the M1 phenotype in 
ovarian carcinoma 330. Treatment of mice bearing mammary carcinoma 4T1-Neu with the 
chemotherapeutic agent docetaxel induced MDSC apoptosis and reprogramming of TAMs to 
M1 331. In another study, HRG (Host-produced histidine-rich glycoprotein) down-regulated 
PIGF (placental growth factor) and skewed TAM polarization to M1 phenotype promoting 
anti-tumor responses and vessel normalization 332. Anti-CD40 Abs in combination with IL-2 
reprogrammed TAMs and up-regulated iNOS in TAMs of lung metastases but not in the 
primary tumor 333. In patients with pancreatic cancer agonistic anti-CD40 Abs activated 
macrophages to infiltrate pancreatic tumors and exert tumoricidal activity in combination 
with chemotherapeutic agent gemcitabine 334. CSF-1 is an important cytokine for macrophage 
survival and M2 polarization. Use of CSF-1R antagonist inhibited the expansion of MDSCs 
and TAMs and their recruitment to lung and prostate tumors 335. Blockade of CSF-1R and 
cKIT receptor tyrosine kinase led to reduced TAM recruitment in a mammary carcinoma 
model 226. In a mouse model of glioblastoma multiforme, inhibition of CSF-1R altered TAM 
polarization to M1 and blocked tumor growth 336. Inhibiting TAMs and their precursor 
inflammatory monocytes through targeting of CSF-1R and CCR2 reduced the number of 
tumor-infiltrating TAMs, but also reprogrammed the remaining TAMs, thus reducing 
metastasis and increased anti-tumor T cell responses in a pancreatic tumor model 337. This 
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TAM-reprogramming approach has shown great promise in improving responses to T cell 
checkpoint immunotherapies using anti-PD-1 and anti-CTLA-4 Abs 338. In another study, 
targeting of CSF-1R enhanced anti-tumor responses of adoptively transferred T cells 339. In 
Paper II we use mAbs to target scavenger receptor MARCO in order to reprogram M2 TAMs 
in the TME. 
1.4.3 Exosomes in cancer immunotherapy 
The release of extracellular vesicles is a way of intercellular communication employed by 
many different cell types. Exosomes are 30-100nm vesicles consisting of a lipid bilayer 
membrane that derive from the late endosomal compartment. They are shed from different 
types of cells, including APCs and tumor cells, during both physiological and 
pathophysiological conditions. Exosomes can carry membranous proteins on their surface 
that are involved in membrane transport, fusion, adhesion, Ag-presentation and immune 
stimulation. They can also contain cytosolic proteins, lipids and RNA molecules. Depending 
on the cell of origin and its activation state, their composition may vary. As a result, they 
have various immunomodulatory activities, which also depend on their cargo. These range 
from cell-cell communication to immunomodulation, and acting as shuttles for Ag-
presentation, transfer of proteins, mRNA and microRNA.  
The observation that exosomes originating from APCs, such as DCs and B cells, carry MHC-
I and -II as well as co-stimulatory molecules on their surface, suggested that they are involved 
in direct Ag-presentation to T cells. In fact, in a mouse model of melanoma tumor-peptide 
pulsed DC-derived exosomes exhibited potent immunostimulatory and anti-tumor capacity 
leading to activation of T cell effector functions and tumor growth inhibition 340. 
Alternatively, exosomes can indirectly activate T cell by enhancing the Ag-presenting 
capacity of DCs. It has been shown that exosomes that are taken up by immature DCs 
transfer their antigenic load to endogenous MHC molecules, which are then transported to the 
surface of the DC and present Ag in the classical manner to stimulate T cells 341.  
Tumor-derived exosomes have been suggested to both promote and suppress Ag-specific and 
non-specific anti-tumor responses. For example, tumor-derived exosomes are enriched for 
receptors that induce T cell apoptosis, such as TNF-related apoptosis-inducing ligand 
(TRAIL) and CD95, leading to suppression. Additionally, they can promote the 
immunosuppressive TME as they are enriched in factors such as prostaglandin E2 and TGF-β 
that drive the generation of MDSCs and M2 polarization of TAMs 342. Also, as carriers of 
mRNA and microRNA molecules, exosomes have the capacity to regulate the transcription of 
different genes in the recipient cells. For example tumor-derived exosomes carrying miR-21 
can bind to TLR7 and 8 activating macrophages in the TME to produce TNF, IL-6 and 
thereby lead to increased tumor growth and metastasis 343. Tumor-derived exosomes also 
facilitate tumor invasion and metastatic spread by conditioning the distal locations for the 
seeding of micrometastases, as has been shown in the case of melanoma-derived exosomes 
that accumulate in draining lymph nodes 344,345.    
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However, exosomes carrying tumor-Ags have also been shown to activate DCs to induce 
potent CTL anti-tumor responses 346. Moreover, experimental approaches have tried to 
generate immunogenic exosomes by pulsing APCs in vitro with tumor-derived Ags, aiming 
to induce Ag-specific immune responses against the tumor. It has been shown that activation 
of B cells is necessary for the efficient induction of T cell responses to exosome-bound Ags 
347. Additionally, exosomes have also been described as potent inducers of inflammatory 
cascades and could thus be used as adjuvants as they carry a wide array of stimuli that lead to 
immune activation. These can be inflammatory mediators (cytokines such as IL-1β), 
microbial Ags that are ligands for PRRs and TNF-related proteins (FasL, TRAIL, CD40L).  
Immunotherapeutic approaches focus on attempts to modulate exosome composition, release 
and cell targeting capacity, as well as modulating the activity of the APC that they originate 
from by cytokines, Ag-stimulation, gene transfer and microRNA pulsing, as has been 
reviewed elsewhere 348,349. In Paper IV we use DC-derived exosomes loaded with αGC and 
the model Ag OVA in a vaccination approach to induce Ag-specific anti-tumor responses.   
1.5 MURINE MODELS OF HUMAN MELANOMA, BREAST AND COLON 
CANCER  
Breast cancer is the most common cancer in women (second most common cancer overall), 
with 1.7 million new cases and representing 25% of all cancers in women in 2012. Melanoma 
accounts for 1.6% of all cancers and colon cancer is the third most common cancer, 
representing 9.7% of all cancer cases in 2012, (source: www.wcrf.org). 
Studies on murine tumor models have shown that metastatic patterns of different cancer cell 
lines are not random, but rather site specific and depend on the site of injection of the tumors 
cells, thus taking into account the local tissue-specific microenvironment and supporting the 
use of orthotopic models in cancer research 350,351. However, this is not always an easy task. 
For several reasons the below-mentioned models were assessed as valid to explore the 
hypotheses described in this thesis.  
1.5.1 Mouse models of melanoma (B16) 
The B16 melanoma cell line was derived from a spontaneous C57BL/6 tumor and is a widely 
used model in melanoma studies 352,353. It is known for its aggressive growth and being 
difficult to treat. The cells can either be inoculated subcutaneously in the flank of a mouse to 
generate a primary tumor or intravenously to simulate a metastatic model of melanoma in the 
lung.  B16 exists in many different variants, the difference being their metastatic potential. 
The most commonly used is the B16.F10, which metastasizes from the primary subcutaneous 
tumor to the lymph nodes and lungs. B16 is a rather plastic cell line and the degree of 
pigmentation may vary, however this does not seem to influence the expression of different 
TAAs. B16 expresses many of the TAAs that human melanomas express, making it a good 
model system for the human disease. One of the TAAs expressed on the surface of B16 cells 
is glycoprotein 75 or TRP-1. The surface molecule gp75, is targeted by Abs of the TA99 
IgG2a clone (used in Paper II) which when bound trigger its internalization and mediate 
ADCC by NK cells 354. This antibody clone is used as a golden standard (positive control) in 
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many immunotherapy settings tested in the B16 model. The B16 cell line exists in many 
functional variants genetically modified to express different genes of interest, such as GFP, 
luciferase, Flt3L, GM-CSF and soluble or membrane-bound ovalbumin. This makes it a very 
versatile and useful model system. B16 expresses low levels of MHC-I 355 and MHC class II 
expression can be induced by IFNγ 356. B16 is a low- or non-immunogenic tumor. The B16 
melanoma model is a widely used model with many modified version that allow flexibility in 
functional read-outs, such as the OVA-expressing and the luciferase-tagged variants that are 
used in Papers II and IV.  
1.5.2 Mouse model of breast cancer (4T1) 
The 4T1 mammary carcinoma cell line was derived from a cell line that originated from a 
spontaneous tumor of a MMTV Balb/c mouse, which was transplanted to a C3H mouse 
357,358. It is a typical triple negative mammary carcinoma cell line with a mesenchymal 
phenotype (ER-/PR-/HER2-), the most challenging to treat type of breast cancer. As shown in 
Paper II, the MARCO receptor is highly expressed in triple negative human breast cancer, 
making 4T1 a relevant experimental model to study the effect of MARCO-targeting. 4T1 was 
selected for being easy to culture, highly tumorigenic when inoculated into mice, resistant to 
6-thioguanine and for its capacity to metastasize to distal sites. There are several reasons that 
make the 4T1 cell line a suitable model for human breast cancer. Firstly, it can be readily 
introduced orthotopically into the mammary fat pad of mice and can metastasize from the 
primary tumor site to several sites (lymph nodes, bone, brain liver and lungs) in a pattern 
similar to human mammary carcinomas. Moreover, after inoculation the disease process 
progresses over a period of several weeks modeling the human setting. Much like many 
human cancers, 4T1 tumors are poorly immunogenic, which means that treatment with 
irradiated tumor cells fails to mount a memory response against a secondary introduction of 
the same tumor.  4T1 cells express MHC-I but not MHC-II, making them good targets for 
CD8+ CTLs and NK cells.  Finally, as metastatic disease is of great importance to study, a 
great advantage comes from being able to excise the primary tumor in order to generate a 
model for metastatic disease simulating the human setting where surgical removal of the 
primary tumor proceed any other treatment step.  
1.5.3 Mouse model of colon cancer (MC38) 
The MC38 colon adenocarcinoma cell line was established in a C57BL/6 mouse using 
dimethyl-hydrazine (DMH). DMH 0.2mg/mouse was injected subcutaneously (s.c.) weekly 
for 7 moths. Formed colon tumors were excised and passaged and the ones that survived the 
first passage went on to serial transplants. The MC38 tumor was the only small tumor to 
survive the first passage and was transplanted by trocar to the axillary region. MC38 was 
characterized as a grade III adenocarcinoma of the colon, which is highly metastatic to the 
lung 359. However, intraperitoneal transplantation gave rise to hepatic metastases, indicating 
that the site of implantation affects the metastatic pattern. MC38 has been extensively used in 
studies of checkpoint therapies with anti-CTLA-4, anti-PD-1 and anti-PD-L1 Abs, and thus 
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was assessed as a relevant model to compare combination therapies of anti-CTLA-4 and anti-
MARCO Abs in Paper II.   
1.5.4 Mouse model for the study of EMT and metastasis 
To study the complexity of the metastatic process, where the evaluation of tumor cell motility 
and the ability to colonize distal sites is imperative, perhaps the most physiological assay is 
the injection of tumor cells sub-cutaneously or in the footpad. This route of injection gives 
direct access into the lymphatics, where the first stop is the popliteal lymph node. This model 
was used to compare the migratory capacity of cell lines with different EMT profiles in Paper 
III. EpH4 is a non-invasive non-migratory cell line derived by immortalization of balb/c 
mammary epithelial cells 360.  EpRas cells were generated by transducing the parental EpH4 
cells with a retroviral vector expressing v-Ha-ras 361. Upon stimulation with TGF-β these 
cells gain migratory capacity. Finally, EPXT cells are stably in EMT under the influence of 
oncogenic Ras and autocrine TGF-β-signaling.  
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2 THE PRESENT STUDY 
2.1 AIMS 
This thesis aims to identify novel candidates in the tumor microenvironment for targeted 
immunotherapy of cancer.  
Specific aims: 
Paper I - To investigate the impact of monoclonal antibodies targeting scavenger receptor 
MARCO on marginal zone macrophages and adaptive immune responses.  
Paper II - To modulate the immunosuppressive tumor microenvironment into induction of 
anti-tumor immune responses by using monoclonal antibodies to scavenger receptor 
MARCO targeting tumor-associated macrophages.  
Paper III - To investigate the role of TGF-β1-induced epithelia-mesenchymal transition on 
lymphatic metastasis of cancer cells. 
Paper IV - To evaluate the immunomodulatory role of exosomes as cancer vaccines, 
triggering tumor-specific adaptive immune responses. 
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2.2 RESULTS AND DISCUSSION 
2.2.1 Marginal zone macrophages regulate antigen transport by B cells to 
the follicle in the spleen via CD21 (Paper I) 
The presence of anti-MARCO autoantibodies has previously been reported in SLE patients, 
however, their role in the pathogenesis of autoimmune disease is still unknown. In this 
study we investigate the possible regulatory effects induced by the anti-MARCO Abs on 
other immune cells in responses to foreign Ags. MZMs are strategically positioned at the 
marginal sinus of the spleen where they capture incoming Ag from the circulation via 
scavenger receptor MARCO and interact with MZBs. Based on this, we therefore set out to 
investigate the effect of anti-MARCO Abs on the MZM/MZB interplay. 
To study the effects of MARCO-crosslinking on the MZM/MZB interaction, a rat anti-
mouse MARCO Ab was injected intravenously (i.v). in wildtype (wt) mice. The Ab 
selectively bound to MARCO-expressing MZMs in the MZ without depleting them. This 
resulted in the gradual loss of CD21 (complement receptor 2) on MZBs, and to a lesser 
extent on other B cell populations, already one hour after administration. The loss of CD21 
could not be attributed to local complement activation, blocking of antibody binding, or 
internalization of CD21. It was also solely targeting CD21, leaving its alternative splice-
variant, CD35 on FDCs unaffected. A similar CD21 loss was observed also with polyclonal 
mouse serum containing Abs against MARCO, thus excluding inter-species cross-
reactivity. Since MARCO can be up-regulated in response to LPS-stimulation, we 
investigated the involvement of MyD88-, TLR2-, TLR4- and TLR9-signalling in mediating 
CD21 loss on MZBs upon MARCO triggering. However, these pathways were not involved 
and we could also exclude the involvement of FcγRs. 
Due to the speed of the response (observed CD21-loss already 1 hour post administration), 
we hypothesized that shedding of CD21 from the surface of MZBs could be the underlying 
mechanism of the CD21 loss. This is known to occur on B cells and soluble CD21 can be 
detected in several inflammatory and autoimmune conditions. Purinergic enzyme receptors 
P2X7 and P2Y have the capacity to cleave CD21 in response to extracellular ATP. Based 
on that, ATP-release after anti-MARCO Ab addition to peritoneal MARCO+ macrophage 
cultures in vitro, was investigated. Extracellular ATP could be detected already 5 minutes 
post stimulation. Moreover, addition of extracellular ATP to splenocyte cultures led to a 
decrease in CD21 levels on MZBs. Increased levels of extracellular ATP are associated 
with pro-inflammatory activation of macrophages, referred to as M1 polarization. This 
suggests that MARCO-engagement leads to macrophage activation. To further investigate 
the effect of the released ATP by the macrophages we assessed the expression of CD39, an 
ectonucleotidase involved in the catabolism of pro-inflammatory extracellular ATP to ADP. 
This metabolic reaction facilitates the transition of macrophages from a pro-inflammatory 
to an anti-inflammatory regulatory state, thus functioning as a homeostatic switch during 
inflammation 362. Interestingly, 24 hours after stimulation of macrophages with anti-
MARCO in vitro, CD39-expression increased to levels similar to those induced by the 
addition of extracellular ATP. This could be regarded as a compensatory mechanism 
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aiming to regulate macrophage activation in response to immunogenic stimuli, such as 
ATP.  
It has previously been shown that MZBs take up Ag and migrate back and forth to the 
follicle depositing Ag on the FDCs. CD21 is an important receptor for opsonization of 
foreign Ags and generation of immune complexes. To assess the impact of CD21 loss in 
response to anti-MARCO engagement on Ag-shuttling, mice were immunized with high 
molecular weight dextran, as a model Ag. Dextran is dependent on CD21 for its uptake by 
MZBs, making it an ideal model-Ag to study complement receptor-dependent 
Agtransportation. Interestingly, pre-treatment with anti-MARCO Abs significantly reduced 
binding of dextran to MZBs, due to the decrease in CD21. Importantly, it also decreased the 
amount of dextran that was deposited on the FDCs. Reconstitution of CD19-deficient mice 
(lacking MZBs) with splenic B cells made it possible to tract the migration of CD19+ MZBs 
upon Ag-stimulation. No differences were observed, suggesting that the ability of MZBs to 
migrate to the follicles of the spleen in response to dextran immunization was not affected 
by the anti-MARCO Ab treatment. In conclusion, MARCO-crosslinking affects the amount 
of Ag that can be captured by MZBs due to the loss of CD21, as well as Ag deposition on 
FDCs in the follicles, while leaving the shuttling capacity of MZBs intact. 
Ag deposition on FDCs is important both for the initiation of the GC reaction and 
consequently also humoral responses. Naturally, we next investigated how the loss of CD21 
on MZBs and the consequent reduction of Ag deposition on FDCs affected the subsequent 
immune response to those Ags. For that, immunization with TI Ag NP-dextran was 
performed after anti-MARCO treatment, at which point the expression of CD21 was 
already lost. Analysis of the subsequent humoral response showed significantly lower 
levels of Ag-specific IgM Abs in mice pretreated with anti-MARCO Abs. This is in line 
with the fact that dextran is primarily bound by MZBs, which respond best to TI Ags.  
Next, we analyzed the humoral response against the TD Ag NP-CGG after anti-MARCO 
injection. In line with our previous results, anti-MARCO injected mice showed a reduction 
in GC B cell numbers compared to controls. This was further reflected in the antibody 
response in treated mice, where lower IgM, IgG1 and IgG3 levels were observed. Thus, 
anti-MARCO Abs have a pronounced effect on the humoral immune response against both 
TI and TD Ags. This suggests that the elevated levels of anti-MARCO autoantibodies 
found in SLE patients could contribute to the increased risk of infection observed in these 
patients. An additional contribution of anti-MARCO Abs to the pathology of SLE could be 
that defective complement receptor expression on B cells leads to inefficient clearance of 
apoptotic cells, which causes a break in self-tolerance.  
In summary, this paper reports a novel mechanism through which, resident MZM in the 
spleen regulate innate and adaptive immune responses to foreign Ags. MZM activation 
through PRR MARCO by Abs leads to ATP-release, cleavage of CD21 on MZBs and 
reduced Ag deposition on FDCs. Since MARCO can also bind self-Ags, a similar 
mechanism could limit their deposition on FDCs. It would therefore be interesting to 
investigate how this pathway can be manipulated to regulate unwanted adaptive immune 
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responses to self-Ags or to enhance protective immunity to prevent infection. Finally, 
crosslinking of MARCO with Abs led to ATP-release, which is associated with M1 
macrophage polarization. This knowledge led to the hypothesis that MARCO can be 
targeted by Abs to induce a switch to a pro-inflammatory phenotype, for example in the 
setting of cancer. 
2.2.2 Reprogramming tumor associated macrophages by antibody targeting 
inhibits cancer progression and metastasis (Paper II) 
Tumors are complex tissues consisting of various types of cells besides the tumor cells. 
TAMs are a heterogeneous population of macrophages and make up the majority of the 
tumor-infiltrating inflammatory myeloid cells that account for the immunosuppressive 
microenvironment of tumors.  
Based on the fact that MARCO expression is restricted to certain macrophage 
subpopulations, we wanted to investigate whether MARCO was also expressed on TAMs 
in the TME. We screened tumor sections of mammary adenocarcinoma, melanoma and 
colon adenocarcinoma tumor model and identified the presence of MARCO on 
macrophages in the tumor stroma. MARCO-expression was only present in a fraction of the 
F4/80+ cells in the tumor stroma, suggesting that the receptor is restricted to a subtype of 
macrophages. To further elucidate the nature of the subset of macrophages that expressed 
MARCO, we sorted the different subsets by flow cytometry. We could identify expression 
of MARCO on the CD11b+ Ly6Clo MHCIIlo subset of tumor infiltrating TAMs. This subset 
showed characteristic expression of typical M2 markers (arg1, fizz1, etc), as well as Cx3cr1 
and low expression of MHC-II, as observed by qPCR.  
In an effort to identify what is driving the up-regulation of MARCO on TAMs, we set up an 
in vitro system for polarization of bone marrow-derived macrophages by cytokines or 
tumor supernatant. Interestingly MARCO expression was up-regulated in M2 and tumor 
supernatant polarized cultures, supporting our in vivo findings.   
Based on the fact that, IL-10 and TGF-β are the major immunosuppressive cytokines in the 
TME and can promote M2 polarization of macrophages, we investigated whether they 
could also drive the expression of MARCO. In vitro cultures of a peritoneal macrophage 
cell line were stimulated with IL-10 or TGF-β and indeed, MARCO expression increased in 
response to both these cytokines.   
Having identified MARCO as a specific marker for M2 TAMs, we generated mAbs to 
MARCO, and evaluated their use in an immunotherapy setting to the three previously 
mentioned tumor models. Anti-MARCO Abs could infiltrate the tumor and bind to 
MARCO+F4/80+ cells. Surprisingly, anti-MARCO treatment led to decreased primary and 
metastatic tumor growth in the mammary adenocarcinoma model 4T1 (Figure 6A and B). 
Moreover, we found that anti-MARCO treatment led to an increase in M1 TAMs and a 
decrease in M2 TAMs. This was accompanied by an increased GC B cell response in the 
tumor-draining lymph node and an increased CD4+h/CD8+ T cell ratio in the tumor, 
suggesting the treatment increased tumor immunogenicity. We did not observe any other 
 42 
significant difference caused by the anti-MARCO treatment when we examined different 
lymphocyte populations infiltrating the tumors (NK, B and T cells, DC, neutrophils) or Mo-
MDSC and PMN-MDSC in the spleens of tumor-bearing mice. 
To further validate the effect of anti-MARCO treatment, we used another tumor model, the 
B16 melanoma. Also here, treatment with anti-MARCO Abs inhibited tumor growth, to a 
similar degree as TA99 Ab, an antibody known to induce ADCC to B16. Moreover, the 
anti-MARCO effect was absent in MARCO-deficient tumor bearing animals, suggesting 
the observed tumor decrease in the treated wt mice was MARCO-specific. Similar 
alterations were observed in the different tumor infiltrating leukocyte populations as in the 
4T1 model, more specifically a decrease in inflammatory macrophages in the tumor and an 
increase in CD4+/CD8+ T cells, CD4+/Tregs, OVA-specific CD8+ T cells and OVA-specific 
IgG2a and b. 
Additionally, the effect of anti-MARCO treatment was assessed in combination with other 
mAb immunotherapies. When combined with TA99 mAbs or immune checkpoint anti-
CTLA-4 Abs we observed an additive tumor growth inhibiting effect. In particular, anti-
MARCO Ab and anti-CTLA-4 Ab combination treatments decreased tumor growth of B16 
melanoma and MC38 colon tumor-bearing mice compared to anti-CTLA-4 Ab 
monotherapy (Figure 6C and D).  
 
 
 
Figure 6. Targeting MARCO by mAbs inhibits in vivo tumor growth and metastasis  
4T1 (mammary carcinoma), B16 (melanoma) or MC38 (colon carcinoma) cells were injected s.c. in mice 
followed by Ab treatment. Tumor growth was monitored by manual measurements. (A) Tumor volume of 4T1 
mammary carcinoma after anti-MARCO Ab treatment (full circles) compared to untreated controls (empty 
circles), on day 21 after tumor inoculation (B) Metastatic index (number of lung tumor colonies/primary tumor 
volume) of 4T1 tumors after anti-MARCO (full circles) compared to untreated controls (empty circles),  on day 
21 (C) Tumor volume of B16 melanoma untreated, anti-CTLA-4 Ab+Gvax and anti-CTLA-4 Ab +Gvax+anti-
MARCO Ab-treated mice, day 12 (D) Volume of MC38 colon cancer untreated, anti-CTLA-4 Ab and anti-
CTLA-4 Ab+anti-MARCO Ab-treated mice, day 10. Described also in Paper II: Fig. 3 and 4.  
 
As many immunomodulatory Ab therapeutics require FcγR involvement to exert their 
function, we generated mouse anti-MARCO Ab variants/mutants with null FcγR-binding 
and observed that the tumor growth inhibiting effect was FcγR-dependent. Utilizing KO 
mice deficient for all or only for activating FcγR we could narrow the effect down to the 
involvement of the inhibitory FcγRIIb. Interestingly, high expression of FcγRIIb correlated 
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with the macrophage subpopulations exhibiting high MARCO expression, namely the in 
vitro M2 BMDM and tumor sorted M2 TAMs, further strengthening our findings. This 
suggests that the anti-tumor activity of anti-MARCO Abs is dependent on the ability of the 
Fc-part of the anti-MARCO Ab to engage the inhibitory FcγRIIB.  
To investigate the potential application of the anti-MARCO Ab treatment in the clinical 
cancer setting we investigated the expression profile of MARCO by gene expression and 
immunofluorescence on human breast cancer and metastatic melanoma biopsies. In the case 
of human breast cancer, using the TCGA and KI/Clinseq datasets we found that higher 
MARCO expression correlated with the basal (triple negative) subgroup of patients. In the 
case of melanoma, higher MARCO expression was observed amongst in the distal 
metastases. Thus in both cancers, MARCO expression is associated with more aggressive 
and metastatic cancer types.  
To further interpret MARCO expression with reference to the metastatic cancer profile, we 
compared MARCO expression relative to an M2 TAM gene signature in the human breast 
cancer and melanoma datasets. Interestingly, MARCO-expression correlated with many M2 
genes as well as with the expression of FcγRIIB, suggesting that MARCO is expressed in 
tumors with a high TAM content. Furthermore, we analyzed MARCO expression relative 
to an EMT gene signature, and observed a correlation with the expression of known EMT 
regulators mmp9, snail and twist.  
Finally, we verified MARCO expression on tumor sections from human breast cancer and 
melanoma patients by immunofluorescence staining. In human breast cancer, we observed a 
higher infiltration of CD68+ macrophages in the stroma of the basal triple negative breast 
cancer compared to the ER+/PR+ subgroup. In addition, MARCO was present on CD68+ 
macrophages and correlated with the presence of the M2 markers CD163, as well as 
CD206, strengthening our hypothesis that MARCO is a marker for M2 TAMs. These data 
suggest that MARCO is a clinically relevant marker for distinguishing aggressive 
metastatic breast cancer and melanoma, and provides a novel candidate for targeted 
immunotherapy using Abs.  
Overall, this study identifies a novel marker for a subset of immunosuppressive TAMs, 
which correlates with metastatic gene signatures in clinical samples of human breast cancer 
and melanoma. Pre-clinical models show a promising decrease in primary and metastatic 
tumor growth, as well as re-programming of TAMs from M2 towards M1 phenotype and 
accompanied by increased tumor-immunogenicity. Moreover, combinatorial treatment 
using anti-MARCO Ab and checkpoint therapy using anti-CTLA-4 Ab showed an 
impressive inhibition of tumor growth and increased overall survival. Altogether, this 
suggests that immunotherapeutic approaches aiming at repolarizing the immunosuppressive 
TME offer a promising new approach to cancer immunotherapy. 
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2.2.3 TGF-β1-induced EMT promotes targeted migration of breast cancer 
cells through the lymphatic system by the activation of CCR7/CCL21-
mediated chemotaxis (Paper III) 
Metastatic cancer disease presents the greatest challenge in treating cancer. Tumor cells 
have the ability to disseminate through lymphatic and the blood circulation during 
metastatic spread. However, it is still unknown whether lymphatic dissemination is a 
targeted process. TGF-β1 is an abundant cytokine in the TME and has been associated with 
metastatic disease in many cancers. TGF-β1-signaling is a known activator of a genetic 
program known as epithelial-mesenchymal transition (EMT), which induces a migratory 
phenotype in tumor cells. Based on this, we hypothesized that TGF-β-induced EMT could 
be connected to lymphatic dissemination of tumor cells.  
To investigate whether TGF-β-induced EMT predisposes tumor cells to metastasize 
through the lymphatics, we used a mouse model frequently used to study DC trafficking to 
draining popliteal lymph nodes (PLN), by injecting tumor cells into the hind footpad of 
mice. For this, three versions of a mammary epithelial cell line, with different EMT 
profiles, were used. EpH4 is non-metastatic in response to TGF-β1, EpRas originates from 
EpH4 but has constitutive oncogenic Ras-signaling and undergoes EMT in response to 
TGF-β1, and EpXT is derived from EpH4 but has constitutive expression of oncogenic 
Ras- and TGF-β1-signaling and is in stable EMT. Fluorescently labeled versions of the cell 
lines were injected into the footpads of mice to assess the migratory capacity to the draining 
PLN. EpXT cells formed tumors at the site of injection but also acquired a migratory 
capacity and were detected in the draining PLN after 2 days. They were primarily located in 
the subcapsular sinuses, indicating entrance through afferent lymphatic vessels. In contrast, 
non-migratory EpH4 cells formed small tumors only at the site of injection and could not be 
detected in lymph nodes. EpRas cells gained migratory capacity only upon pre-treatment 
with TGF-β1. Thus, induction of EMT by TGF-β1-signaling induced a migratory 
phenotype on the tumor cells, which led to lymphatic metastasis.  
 Moreover, immunofluorescence stainings for blood and lymphatic vessels in EpXT 
footpad tumors showed that blood vessels were evenly dispersed within the tumors, while 
lymphatic vessels clustered in certain regions. The areas of lymphatic vessel clustering 
were associated with more invasive/migratory tumor cell morphology and showed evidence 
of intravasation. This suggested that EMT might induce lymphatic metastasis in a targeted 
manner. To investigate this, an in vitro 3D matrix co-culture system was used to study 
migration towards lymphatic endothelial cells (LECs), or vascular endothelial cells (VECs). 
Interestingly, tumor cells undergoing EMT acquired an elongated morphology and formed 
clusters of invasive cells that preferentially migrated towards LECs, compared to VECs. 
Non-EMT cells, on the other hand, did not migrate. Taken together, these results suggest 
that mammary tumor cells that have undergone TGF-β-induced EMT have an increased 
migratory capacity and preferentially migrate in a targeted manner towards lymphatic 
vessels, as opposed to blood vessels. 
It is well established that upon activation by inflammatory stimuli in the periphery, DCs use 
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chemokine receptor CCR7 to respond to a chemokine gradient of its ligand CCL21. The 
CCR7/CCL21 chemotactic axis guides DC migration through lymphatic vessels in order to 
ultimately travel to draining lymph nodes where they initiate adaptive immune responses. 
Based on the fact that breast cancer cells can also express CCR7, we hypothesized that 
CCR7 could have a similar role in guiding the lymphatic dissemination of EMT cells. 
Indeed, both TGF-β1-induced EMT models showed up-regulated expression of CCR7, 
compared to the non-EMT EpH4, suggesting that TGF-β driven CCR7 expression is 
dependent on EMT. To investigate the CCR7/CCL21 chemotactic axis we set up transwell 
invasion assays, in which mammary cancer cells that had undergone TGF-β-induced EMT 
were seeded in the upper chamber and recombinant CCL21, was added in the lower 
chamber as a chemoattractant. Tumor cells that had been treated with TGF-β1 migrated 
more efficiently towards the CCL21 gradient, compared to untreated cells. When a 
neutralizing anti-CCR7 Ab was added to the cultures, the CCR7/CCL21 interaction was 
blocked leading to reduced targeted migration. Similarly, reduced migration of EpXT cells 
was observed in the in vitro 3D migration assay towards LECs in the presence of the 
neutralizing anti-CCR7 antibody, further strengthening our hypothesis. Moreover, in order 
to assess if this was the case also in vivo, we introduced small interfering RNA to silence 
CCR7 in EpXT cells and injected these cells into the mouse footpad. Interestingly, CCR7-
siRNA-treated EpXT cells expressed lower levels of CCR7 and exhibited reduced 
migration to the PLN compared to their untreated counterparts. These data demonstrate that 
the targeted migration of TGF-β1-induced EMT mammary cancer cells to the lymphatics 
depends on the interaction of CCR7 with CCL21. 
TGF-β1-signaling during EMT can be induced through two independent pathways, a Smad-
dependent and a P38 MAPK-dependent pathway. In order to elucidate the underlying 
molecular mechanisms governing CCR7 up-regulation during TGF-β-induced EMT, we 
utilized molecular inhibitors to those pathways. Surprisingly, both Smad3 and p38 MAPK 
inhibitors led to decreased CCR7 mRNA levels during TGF-β1-induced EMT in mammary 
cancer cells. However, when assessing CCR7 protein levels only p38 MAPK had 
significant inhibitory effect, suggesting that factors operating downstream of p38 MAPK 
signaling were involved in inducing CCR7 expression in EMT cells. By gene expression 
analysis we were able to show that AP-1 factors c-Jun and JunB are responsible for the 
CCR7 overexpression as a result of TGF-β1-induction in EMT in mammary cancer cells. 
Moreover, induction of JunB is P38 MAPK dependent. These results highlight the P38 
MAPK pathway as the underlying mechanism of CCR7-mediated chemoattraction and 
lymphatic dissemination of mammary cancer cells having undergone TGF-β1-induced 
EMT. It also demonstrates that P38 MAPK blockade can reverse EMT, thus highlighting it 
as a novel target for pharmacological inhibition to abrogate lymphatic spread of mammary 
cancer cells. Interestingly, TGF-β1-induced EMT mammary cancer cells that retain 
endogenous TGF-β1 production can induce the secretion of CCL21 by lymphatic 
endothelia vessels, thus potentiating their own metastatic spread. This can be regarded as a 
feed back loop driving the lymphatic spread of malignant cells. Finally, histological 
evaluation of human breast cancer tissue sections revealed that CCR7-expression is 
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associated with tumor cells in invasive areas of the tumors with characteristic low 
expression of E-cadherin, suggesting they have undergone EMT. Moreover, analysis of 
microarray data from a cohort of human breast cancers indicated that high expression of 
CCR7 and CCL21 correlates with an EMT gene signature. 
Overall, the results show that tumor cells use a similar mechanism as DCs to gain migratory 
capacity through the lymphatic system in a targeted manner. Furthermore, it identifies p38 
MAPK as a useful candidate for targeted inhibition to limit EMT and lymphatic 
dissemination of tumor cells. TGF-β1-signaling plays a crucial role in driving EMT and the 
up-regulation of CCR7. As previously mentioned, TGF-β1 is highly expressed by several 
cell types present in the suppressive TME, such as TAMs and Tregs. Targeting TGF-β-
producing cells in the TME for reprograming, with approaches such as the one described in 
Paper II, may thus provide additional ways to restrict lymphatic dissemination of cancer 
cells. 
2.2.4 Synergistic induction of adaptive antitumor immunity by codelivery of 
antigen with α-galactosylceramide on exosomes (Paper IV) 
NKT cells are potent regulators of innate and adaptive immune responses. Moreover in the 
context of cancer, they have been implicated in the maturation of DCs facilitating 
subsequent CD8+ T cell anti-tumor responses, as well as in the killing of 
immunosuppressive TAMs. Their function is however often compromised in cancer. Thus 
attempts to re-activate anergized NKT cells are of great interest in cancer immunotherapy. 
NKT cells recognize lipid Ags presented by the MHC-like molecule CD1d. α-GalCer is a 
super-agonist of NKT cell activation, however when administered in a soluble form it leads 
to NKT cell anergy. Exosomes derived from APCs, and DCs in particular, can express 
CD1d and have been explored in immunotherapeutic approaches aiming to activate 
adaptive immune responses towards tumor-Ag. 
To assess the capacity of exosomes to activate NKT cells, we generated exosomes from 
bone marrow–derived DCs from wt and CD1d-KO mice, lacking NKT cells. We next 
loaded exosomes with α-GalCer and the model Ag ovalbumin (OVA) and assessed NKT 
cell activation in vitro. OVA-loaded exosomes (OVA/exo) or α-GalCer-loaded exosomes 
(α-GalCer/exo) were added to splenocytes cultures from Va14 mice, transgenic for the 
iNKT cell receptor. CD1d-proficient α-GalCer/exo induced greater proliferation of iNKT 
cells compared to CD1d-deificient α-GalCer/exo, suggesting iNKT cell activation is in part 
dependent on the presence of CD1d on the surface of exosomes. OVA/exo failed to induce 
NKT activation, indicating that an activating ligand, in this case α-GalCer, for the NKT cell 
TCR is necessary for their activation. CD1d-proficient α-GalCer/exo also induced greater 
IL-4, IFNγ and IL-17A production by splenocytes, compared to the low levels observed in 
response to CD1d-deficient α-GalCer/exo stimulation and no cytokine production by 
OVA/exo stimulation. The results suggest, that α-GalCer/exo potently stimulate NKT cell 
activation, proliferation and cytokine production in part, but not exclusively, through CD1d 
and require exosomal α-GalCer.  
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In an attempt to translate our findings to an in vivo system, we generated DC-derived 
exosomes loaded with αGC and OVA (α-GalCer-OVA/exo) or the CD8+ T-cell-specific 
OVA-peptide SIINFEKL (αGalCer-SIINFEKL/exo). These were injected i.v. in wt 
recipient mice, and proliferation was assessed after 7 days. Splenic NKT cells proliferation 
was only observed in response to exosomes loaded with both α-GalCer and the Ag/Ag-
peptide, suggesting α-GalCer is required for efficient NKT cell proliferation. Up-regulation 
of the activation marker CD69 was observed already after 1 day, while proliferation 
proceeded until day 5 after stimulation and was accompanied by IFNγ production. IL-4 
production was observed only during the first 3 days. iNKT cell activation also led to an 
early activation and proliferation of DCs, NK, and γδ T cells. Our findings suggest that 
αGC-loaded exosomes are potent inducers of iNKT cell responses, as well as DC, NK- and 
γδ T-cell activation and proliferation in vivo. 
α-GalCer/exo stimulation led to increased OVA-specific CD8+ T-cell proliferation, to a 
greater extent compared to α-GalCer-SIINFEKL/exo, which is in line with previous data 
where SIINFEKL/exo did not sufficiently stimulate proliferation of OVA-specific CD8+ T 
cells, due to the lack of B-cell co-stimulation. Moreover, α-GalCer-OVA/exo immunization 
generated increased numbers of SIINFEKL-specific IFNγ producing cells in a CD1d-
dependent manner. These results show that α-GalCer-loaded exosomes boost Ag-specific 
CD8+ T-cell responses via iNKT cells in vivo in a CD1d-dependent manner. Additionally, 
α-GalCer-OVA/exo immunization induced proliferation of CD4+ T cells and T follicular 
helper (Tfh) cells in an iNKT cell–dependent manner, as the response was lower in CD1d-
deficient mice. In line with the role of Tfh in humoral responses, we detected increased 
numbers GC B cells and plasma cells and increased levels of OVA-specific IgG2c Abs.  
Interestingly, when α-GalCer-OVA/exo where compared to soluble α-GalCer and OVA, 
they were more potent activators of adaptive immune responses as observed by increased 
activation of γδ T cells, CD4+ T cells, and OVA-specific CD8+ T cells. A second boost 
injection of α-GalCer-OVA/exo significantly augmented GC B-cell responses as reflected 
in the increased levels of OVA-specific IgG Abs. These results highlight α-GalCer-loaded 
exosomes as more potent adjuvants and Ag-delivery systems for the initiation of adaptive 
immune responses.  
An additional advantage to the use of α-GalCer-OVA/exo in vaccination, was the observed 
lack of NKT cell anergy induction compared to administration of soluble α-GalCer. 
Importantly, in serial vaccinations only α-GalCer-OVA/exo induced a prolonged second 
wave IFNγ-response, which also resulted in an increase in OVA-specific CD8+ T cells, 
when compared to soluble α-GalCer and OVA vaccination. This suggests that α-GalCer-
OVA/exo have a more potent long-term immunostimulatory effect, making them promising 
vaccination vehicles. 
Based on the previous finding that exosome co-delivery of glycolipid and protein Ag 
boosted adaptive immune responses without inducing iNKT-cell anergy, we investigated 
the potential use of α-GalCer-OVA/exo in tumor immunotherapy. Utilizing an OVA-
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expressing B16 melanoma s.c. tumor model we similarly compared the efficiency of α-
GalCer-OVA/exo to induce adaptive anti-tumor responses, relative to independent 
administration of α-GalCer and OVA. Α-GalCer-OVA/exo significantly inhibited tumor 
growth and prolonged the survival of tumor-bearing mice. This was attributed to increased 
numbers of tumor-infiltrating CD8+ OVA-specific T cells and increased serum levels of 
OVA-specific IgG in α-GalCer-OVA/exo treated mice compared to α-GalCer plus OVA 
treated mice. Together these results show that vaccination with α-GalCer-OVA-loaded 
exosomes can provide a promising immunotherapeutic strategy to induce potent adaptive 
anti-tumor responses.   
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2.3 FINAL REFLECTIONS AND FUTURE PERSPECTIVES  
Harnessing the inherent potential of the immune system for the therapeutic benefit of 
cancer patients has long been the goal of intensive research in the field of cancer 
immunotherapy. As previously mentioned, active immunotherapy poses great challenges 
but holds greater potential with regards to obtaining durable responses in cancer patients. A 
plethora of pre-clinical and clinical studies suggest that activation of early innate immune 
responses appears to be a prerequisite for the induction of potent adaptive immunity with a 
long-term memory component. Thus, combinatorial treatment approaches targeting 
multiple components of the TME are more favorable. Therefore, the focus of this thesis has 
been to identify and evaluate novel targets in the TME, which can be modulated to induce 
the activation of anti-tumor immune responses and to ultimately constrict tumor growth and 
metastasis. 
Paper I describes a mechanism regulating the interplay between MZMs and MZBs in the 
spleen, through the use of Abs to scavenger receptor MARCO. This study provides insight 
into how manipulating this interaction can affect Ag presentation and adaptive immune 
responses to foreign but also to self-Ags. It also identifies a novel tool to regulate macrophage 
activation, with implications for future immunotherapeutic approaches aiming to regulate 
innate immune responses or to increase protective immunity. More specifically, the use of 
anti-MARCO Ab triggers the release of extracellular ATP by marginal zone macrophages. In 
the TME, a shift towards a higher extracellular ATP concentration can be crucial as it drives 
anti-tumor responses. Extracellular ATP is taken up by purinergic P2X7 receptors on DCs, 
leading to inflammasome activation and increased production of pro-inflammatory cytokines 
IL-1β and IL-18 363. IL-1β together with Ag presentation leads to increased NK cell 
proliferation IFNγ-production and activation of CD8+ tumoricidal T cells. ATP also induces 
macrophage maturation and M1 polarization, and increased secretion of IFNγ and IL-17 by T 
cells. In contrast, adenosine leads to reduced production of IL-12 and increased levels of IL-
6, IL-8, IL-10, TGF-β and VEGF by DCs, reduced NK cell cytotoxicity, M2 macrophage 
polarization, decreased cytotoxic T cell proliferation and effector function, and finally 
increased generation of Tregs.  
Paper II identifies scavenger receptor MARCO as a specific marker for the 
immunosuppressive M2 TAM phenotype. MARCO is expressed on TAMs in the TME of 
mammary carcinoma, melanoma and colon carcinoma tumor models. Use of Abs to target 
MARCO significantly inhibited tumor growth and metastasis, and increased survival in 
combination treatments with checkpoint therapy with anti-CTLA-4 Ab. This effect is 
attributed to reprograming of TAMs from an immunosuppressive M2 towards an 
immunostimulatory M1 phenotype characterized by the production of pro-inflammatory 
cytokines. This is in line with the findings of Paper I, and suggests that anti-MARCO Ab 
could use the same mechanism of ATP-release to stimulate the polarization of M2 TAMs to 
M1, thus relieving immunosuppression in the TME. Finally, it identifies MARCO as a 
clinically relevant target in highly invasive and metastatic subtypes of human breast cancer 
and melanoma. There, MARCO expression correlates with an M2 TAM gene profile and 
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increased expression of EMT-associated genes. EMT, as is further discussed in Paper III, is a 
process involved in the acquisition of migratory properties by tumor cells. This suggests that 
TAMs, and in particular MARCO-expressing TAMs, can be a link explaining the more 
invasive phenotypes of those cancers, but also provides a tangible target for immunotherapy. 
Further studies investigating the relevance of MARCO in other human cancers as well as 
elucidating the underlying mechanism of action and pathways involved in MARCO-signaling 
are warranted and will increase our understanding of its role in the TME. These will evaluate 
new combinatorial immunotherapeutic treatments and provide a solid basis for future 
translation of these findings into the clinical setting. 
Paper III elucidates the mechanism through which TGF-β1, a major immunosuppressive 
cytokine in the TME and the driving force for EMT, regulates targeted lymphatic metastasis 
of breast cancer cells. TGF-β controls the CCR7/CCL21 chemotactic axis that guides tumor 
cells to metastasize through the lymphatic system in an EMT-dependent manner. This study 
highlights TGF-β1 as a candidate for targeted pharmacological inhibition in an approach to 
restrict lymphatic metastasis of tumor cells. As was already mentioned TGF-β1 is one of the 
major immunosuppressive cytokines produced by TAMs. Additionally, macrophages have 
been implicated in the induction of EMT in pancreatic tumor cells tumor cells and promote 
invasion and metastasis of mammary carcinoma cells by inducing an inflammatory signature 
that facilitates metastasis 364. Although metastasis-promoting TAMs may be a different 
subtype from the immunosuppressive TAMs, combining the knowledge acquired from Paper 
II and III to treat cancer with anti-MARCO Ab in combination with molecular inhibitors of 
TGF-β may significantly abrogate metastatic disease.  
Paper IV explores the use of DC-derived α-GalCer-loaded exosomes as a vaccination 
approach. This study demonstrates that CD1d+ DC-derived exosomes expressing loaded 
with α-GalCer can be used as adjuvants and are potent inducers of iNKT, CD8+ and CD4+ T 
and B cell responses that ultimately restrict tumor growth. In a similar manner one could 
envisage the design of anti-MARCO Ab-carrying exosomes specifically targeting M2 
TAMs, containing immunostimulatory receptors or microRNA125, -155 or -378, to induce 
M1 polarization. Overall, exosomes provide a flexible vehicle for delivery of ”messages” 
which can be customized to the disease setting and the target of interest.  
In conclusion, the immunotherapy approaches described in this thesis provide new insight 
into mechanisms of innate and adaptive immune regulation, identify novel targets to 
reprogram the immunosuppressive TME, elucidate genetic programs driving lymphatic 
metastasis, as well as harness endogenous cellular products and amplify their modulatory 
capacity. Altogether, this thesis aims to contribute with novel insight into the inner 
workings of several components of our immune system, which can be used in the design of 
future approaches to cancer immunotherapy.  
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3 POPULAR SCIENTIFIC SUMMARY 
English  
The term cancer was coined by the Father of Medicine, the Greek physician Hippocrates of 
Kos (460-370 BC), who first used the words "karkinos" and "karkinoma" to describe tumors. 
In greek, the word karkinos means crab and refers to the similarity observed between the 
branch-like spread of tumors and the shape of a crab.  Although primary cancers can be 
treated by several different means, it is the metastatic cancer disease that is the ultimate 
elusive culprit that makes cancer an incurable disease. However, recent advances in the field 
of cancer immunotherapy, in particular, have lead to new treatment that awaken the patient’s 
own immune system to fight off cancer.  
The immune system is a complex network of cells and molecules that are responsible for 
protecting us against pathogens. In the case of an invasion the immune system recruits 
specialized cells to the site of invasion in order to mount a defense response to combat the 
invader. This phenomenon is known as inflammation. Cancers can also mobilize a similar 
type of inflamamtion, recruiting immune cells to sites of tumor growth. However, immune 
cells in the cancer microenvironment fail to recognize cancer as a threat and instead are 
sequestered by the cancer to support its growth and metastasis. Strategies to awaken the 
body’s own immune system to fight cancer  are therefore of great importance. This thesis 
focuses on identifying new targetd to activate the immune system to combat cancer.  
Paper I, studies two types of immune cells, the macrophages and the B cells, located in the 
spleen. Macrophages (form the greek: makros large and phagein eat) are the big eaters of our 
immune system. They are responsible for taking up and discarding bacteria, dead cells, and 
metabolic biproducts form our blood circulation which would otherwise harm us if they 
reached large amounts. They are therefore found in strategy location in our bodies where the 
blood flows through and can be filtered by macrophages, such as the spleen. This janitorial 
function is mediated, amongst other, by the so called scavenger receptor MARCO, a 
molecule found on the surface of macrophages. B cells are a type of immune cells that have 
the capacity to recognize pathigens and generate specific responses against them by 
producing target-seeking molecule, antibodies. MARCO can however be falsely attacjed by 
target seeking molecules, antibodies, as is the case for example in the autoimmune disease 
SLE. This study shows that, simulating SLE by administering antibodies against MARCO 
has a profound negative effekt on the function of B cells and restricts the specific responses 
they generate agains pathogens. This may provide an explanation as to why SLE patients 
suffer from recurrent infections. 
While macrophages have an important defense and janitorial fucntion, they are also the major 
culprits of inflammation that drives cancer growth and metastasis.  In paper II, we found that 
some macrophages, in the tumor bed of breast and colon cancer as well as melanoma (skin 
cancer), express MARCO. Thus, we used the same target-seeking molecules, antibodies, as 
before to target MARCO on macrophages that are present in the tumor, in order to re-activate 
them against the tumors. Interestingly, antibodies found a subpopulation of macrophages in 
the tumor bed.  Serial treatments with MARCO antibodies, as well as with antibodies that 
activate other immune cells, lead to the re-education of macrophages. This way they started 
producing molecules which activated other immune cells against the tumor, instead of 
suppressing them. This lead to significanlty less tumor growth and metastasis. The presence 
of MARCO is associated with the most aggressive types of breast cancer and melanoma, 
which cause metastasis and are hard to treat. This study shows that MARCO is a target that is 
present in three different types of cancer and that antibodies can be used as a specific tools to 
target MARCO-macrophages in the tumor. This may provide a useful future cancer therapy.  
Cancer cells can grow locally or travel thorugh the blood and lymphatic system to distal sites 
of the body where they seed metastases. Not all cancer cells become metastatic, but the ones 
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that do have to activate a particular gene program in order to gain the capacity to migrate. 
This gene programis normally active during fetal development, when cells need to travel to 
different site of the developing foetus in order to form different organs, and is known as 
epithelia-mesenchymal transition (EMT). The wrongfull activation of EMT is attributed to 
the production of the signaling molecule TGF-β by cancer cells and other sequestered 
immune cells, such as macrophages, in the tumor bed. In paper III we studies the effect of 
TGF-β on breast cancer cells.  Indeed breast cancer cells that only grew locally, changed form 
and gained a migratory capacity because of TGF-β. Interestingly the mickicked another type 
of immune cell, the dendritic cells, whose primary role is to take up pathogens and travel 
through the lymphatic system to major immune cell hubs, where they present the pathogen 
and activate specific immune responses against it. In a similar way, TGF-β activating of 
EMT, lead to the guided entry of cancer cells into the lymphatic system and gave them access 
to travel to distal sites of the body where they could seed new tumors.  
Exosomes are small vesicles that are released by many different type of cells in our bodies. 
They act as a means of communication, transporting various molecular messages between 
different cells. Because of this they can be used to load specific/custom molecules which can 
target specific immune cells and different types of immune repsonses. In paper IV,  we used 
exosomes generated from dendritic cells, which are known to present foregn molecules to 
activated immune responses. These were loaded with α-GalCer, an activator of a type of 
immune cell known as NKT cells. Vaccination using exosomes loaded with α-GalCer lead to 
a more efficient activation of NKT cells, but also several other immune cells, than what α-
GalCer alone would have caused. This was particularly important in the tumor setting, where 
exosomes loaded with α-GalCer as well as a molecule expressed by the tumor, activated 
immune cells against the tumor leading to less tumor growth.  
In summary, this thesis identifies new targets in the tumor microenvironment, which can be 
used to improve the design of future cancer therapeutics for the benefit of cancer patients.  
Svenska 
Ordet cancer kommer ursprungligen ifrån läkekonstens fader, den grekiska läkaren 
Hippokrates av Kos (460-370 f.Kr.), som först använde termerna "karkinos" och "karkinoma" 
för att beskriva tumörer. Det grekiska ordet karkinos betyder kräfta och hänvisar till likheten 
som observerats mellan  spridningsgrenarna i tumörer och formen på en kräfta. Även om 
primärtumörer kan behandlas på flera olika sätt, är det den metastaserande cancersjukdomen 
som är den ultimata skyldige som gör cancer till en obotlig sjukdom. Men de senaste 
framstegen i forskningsfältet om cancer immunterapi, i synnerhet, har lett till nya 
behandlingar som aktiverar patientens egna immunförsvar till att kämpa mot cancer. 
Immunsystemet är ett komplext nätverk av celler och molekyler som är ansvariga för att 
skydda oss mot patogener. När en invasion inträffar rekryterar immunsystemet specialiserade 
celler till platsen för invasionen sker för att att bekämpa inkräktaren. Detta fenomen kallas 
inflammation. Cancer kan också mobilisera en liknande typ av inflamamtion, dvs rekrytera 
immunceller till platser av tumörtillväxt. Men immunceller i cancer mikromiljön lyckas inte 
känna igen tumören som ett hot och istället angrips de av tumören för att stödja dess tillväxt 
och metastasering. Strategier för att väcka kroppens egna immunsystem för att bekämpa 
cancer är därför av stor betydelse. Denna avhandling fokuserar på att identifiera nya 
målmolekyler som kan aktivera immunsystemet för att bekämpa cancer. 
I studie I, studeras två typer av immunceller, makrofager och B-celler, som befinner sig i 
mjälten. Makrofager (från grekiska: makros stor och phagein äta) är storätarna i vårt 
immunsystem. De är ansvariga för att ta upp och gör sig av med bakterier, döda celler och 
metabola biprodukter från blodcirkulationen som annars skulle skada oss om de uppnådde 
stora mängder. Därför befinner makrofager sig i strategiska positioner i våra kroppar där 
blodet flyter igenom och kan filtreras, såsom i mjälten. Denna vaktmästerifunktion medieras, 
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bland annat, av den så kallade scavenger receptor MARCO, en molekyl som finns på 
makrofagernas yta. B celler är en typ av immunceller som har kapaciteten att känna igen 
patogener och generera specifika svar mot dem genom att producera målsökande molekyler, 
antikroppar. MARCO kan dock felaktigt bli attackerad av dessa antikroppar, vilket är fallet 
till exempel i den autoimmuna sjukdomen SLE. Denna studie visar att simulering av SLE 
genom att administrera antikroppar mot MARCO har en stark negativ effekt på B cellers 
funktion och begränsar det specifika svaret som genereras mot patogener. Detta kan ge en 
förklaring till varför SLE-patienter lider av återkommande infektioner. 
Medan makrofager har en viktig försvars- och vaktmästerifucntion, de är också de stora 
skyldiga till inflammationen som driver cancertillväxt och metastasering. I studie II, fann vi 
att vissa makrofager, i tumörbädden av bröst- och tjocktarmscancer, samt melanom 
(hudcancer), uttrycker MARCO. Därför använde vi samma antikroppar som tidigare, mot 
MARCO på makrofager som finns i tumören, för att återaktivera dem mot tumörer. Intressant 
nog fann dessa antikroppar en subpopulation av makrofager i tumörbädden. En serie 
behandlingar med MARCO antikroppar, liksom med antikroppar som aktiverar andra 
immunceller, ledde till omskolning av makrofagerna. På så sätt började de producera 
molekyler som aktiverade andra immunceller mot tumören, i stället för att undertrycka dem. 
Detta ledde till significant mindre tumörtillväxt och metastas. Närvaron av MARCO är 
förknippad med de mest aggressiva typer av bröstcancer och melanom, som orsakar 
metastaser och är svåra att behandla. Denna studie visar att MARCO är ett mål som finns i tre 
olika typer av cancer och att antikroppar riktade mot denna kan användas som särskilda 
verktyg för att omvandla MARCO-makrofager i tumören. Detta kan därför bli en användbar 
framtida cancerterapi. 
Cancerceller kan växa lokalt eller färdas genom blodet och det lymfatiska systemet till 
avlägsna ställen i kroppen där de utsäder metastaser. Inte alla cancerceller blir 
metastaserande, men de som gör det måste aktivera ett särskilt genetiskt program för att få 
förmågan att migrera. Detta genetiska programm är normalt aktivt under fosterutvecklingen, 
då celler behöver resa till olika platser i det växande fostret för att bilda olika organ, och är 
känt som epitel-mesenkymal övergång (EMÖ). Den felaktiga aktivering av EMÖ i cancer är 
beroende av produktionen av signaleringsmolekylen TGF-β utav cancerceller och andra 
sekvestrerade immunceller, såsom makrofager, i tumörbädden. I studie III, studerar vi 
effekten av TGF-β på bröstcancerceller. Vi observerade att bröstcancerceller som endast 
växte lokalt, ändrade form och fick en vandrande kapacitet på grund av TGF-β. Intressant 
nog, härmade de en annan typ av immunceller, de dendritiska cellerna, vars främsta roll är att 
ta upp patogener och färdas genom det lymfatiska systemet till stora immuncellsnav, där de 
presenterar patogener och aktiverar specifika immunsvar mot dem. På ett liknande sätt, leder 
TGF-β aktiverad EMÖ, till en guidad migrering av cancerceller som ger  inträde till 
lymfsystemet och ger dem möjlighet att färdas till avlägsna ställen i kroppen där de kan 
utsäda nya tumörer. 
Exosomer är små blåsor som frigörs av många olika typer av celler i våra kroppar. De 
fungerar som ett kommunikationsmedel, som transporterar olika molekylära meddelanden 
mellan olika celler. På grund av detta kan de användas för att laddas med specifika molekyler 
som kan riktas mot särskilda immunceller och ge upphov till olika typer av immunsvar. I 
studie IV, använde vi exosomer som genereras från dendritiska celler, som är kända för att 
presentera främmande molekyler för att aktivera immunsvar. Dessa laddades med α-GalCer, 
en molekyl som aktiverar en typ av immunceller som kallas NKT celler. Vaccination med 
hjälp av exosomer laddade med α-GalCer ledde till en mer effektiv aktivering av NKT celler, 
men även av flera andra immunceller, än vad α-GalCer enbart skulle ha orsakat. Detta var 
särskilt viktigt i tumörmiljön, där exosomer laddade med α-GalCer samt en molekyl som 
uttrycks av tumören, aktiverade immunceller mot tumören och ledde till mindre 
tumörtillväxt.  
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Sammanfattningsvis, identifierar denna avhandling nya mål i cancermikromiljön som kan 
användas för att förbättra framtida cancerterapier till förmån av cancerpatienter.  
Ελληνικά 
Η λέξη καρκίνος ορίστηκε από τον Πατέρα της ǿατρικής, τον Έλληνα ιατρό ǿπποκράτη τον 
Ȁώο (460-370 π.Χ.), ο οποίος χρησιμοποίησε για πρώτη φορά τους όρους "καρκίνος" και 
"καρκίνωμα" για να περιγράψει όγκους. Ο συμβολισμός βασίζεται στην ομοιότητα που 
παρατηρείται μεταξύ των διακλαδώσεων εξάπλωσης των όγκων και του σχήματος του 
καρκίνου. Αν και οι πρωτογενείς όγκοι μπορούν να αντιμετωπιστούν με αρκετούς 
διαφορετικούς τρόπους, η μεταστατική ασθένεια του καρκίνου είναι ο τελικός ένοχος που 
καθιστά τον καρκίνο ανίατη νόσο. Ωστόσο, πρόσφατες πρόοδοι ειδικά στον τομέα της 
ανοσοθεραπείας του καρκίνου, έχουν οδηγήσει στην ανάπτυξη νέων θεραπειών που ξυπνούν 
το ανοσοποιητικό σύστημα του ασθενούς έτσι ώστε αυτό να καταπολεμήσει τον καρκίνο. 
Το ανοσοποιητικό σύστημα είναι ένα πολύπλοκο δίκτυο κυττάρων και μορίων που είναι 
υπεύθυνα για την προστασία μας έναντι των παθογόνων. Σε περίπτωση παθογόνας εισβολής 
το ανοσοποιητικό σύστημα στρατολογεί εξειδικευμένα κυττάρα στην συγκεκριμένη 
τοποθεσία προκειμένου να ενεργοποιήσει μια ανοσοαπόκριση για την καταπολέμηση του 
εισβολέα. Αυτό το φαινόμενο είναι γνωστό ως φλεγμονή. Ο καρκίνος μπορεί επίσης να 
κινητοποιήσει έναν παρόμοιο τύπο φλεγμονής, προσελκύοντας κύτταρα του ανοσοποιητικού 
συστήματος στους τόπους ανάπτυξης του όγκου. Εντούτοις, τα κύτταρα του ανοσοποιητικού 
συστήματος στο μικροπεριβάλλον του καρκίνου αποτυγχάνουν να αναγνωρίσουν τον 
καρκίνο ως απειλή και αντίθετα χειραγωγούνται από τον καρκίνο έτσι ώστε να σθνεισφέρουν 
στην ανάπτυξη και μετάστασή του. Η ανάπτυξη στρατηγικών για την αφύπνιση του 
ανοσοποιητικού συστήματος του οργανισμού για την καταπολέμηση του καρκίνου είναι, 
επομένως, ύψιστης σημασίας. Η συγκεκριμένη διατριβή εστιάζει στον εντοπισμό νέων 
στόχων για την ενεργοποίηση του ανοσοποιητικού συστήματος ως προς την καταπολέμηση 
του καρκίνου. 
Η πρώτη μελέτη, εστίαζεται σε δύο τύπους κυττάρων του ανοσοποιητικού συστήματος, τα 
μακροφάγα και τα Β λεμφοκύτταρα, που βρίσκονται στο σπλήνα. Τα μακροφάγα (από το: 
Ȃακρός και φαγείν) είναι αδηφάγα κύτταρα του ανοσοποιητικού συστήματος. Είναι 
υπεύθυνα για την ανάληψη και την απόρριψη βακτηρίων, νεκρών κυττάρων και 
μεταβολικών παραπροϊόντων από την κυκλοφορία του αίματος, που διαφορετικά θα μας 
έβλαπταν αν έφταναν μεγάλες ποσότητες. Ως εκ τούτου, βρίσκονται σε στρατηγικές 
τοποθεσίες, όπου το αίμα εισέρχεται και διηθείται από τα μακροφάγα, όπως ο σπλήνας. Αυτή 
η καθαρτική λειτουργία των μακροφάγων εξασκείται, μεταξύ άλλων, από το λεγόμενη 
υποδοχέα-καθαριστή MARCO, που βρίσκεται στην επιφάνεια των κυττάρων αυτών. Τα Β 
λεμφοκύτταρα είναι ένας τύπος κυττάρων του ανοσοποιητικού που έχουν την ικανότητα να 
αναγνωρίζουν και να παράγουν ειδικές αποκρίσεις ενάντια στα παθογόνα, κυρίως μέσω της 
παραγωγή αντισωμάτων. Ο MARCO μπορεί ωστόσο να προσδεθεί λανθασμένα από 
αντισώματα, όπως συμβαίνει για παράδειγμα στην αυτοάνοση ασθένεια του συστηματικού 
ερυθυματώδους λύκου (ΣΕȁ). Αυτή η μελέτη δείχνει ότι, η προσομοίωση του ΣΕȁ μέσω της 
χορήγησης αντισωμάτων εναντίον του MARCO, έχει σοβαρές αρνητικές επιπτώσεις στη 
λειτουργία των Β λεμφοκυττάρων και περιορίζει τις ειδικές ανοσοαποκρίσεις που εξασκούν 
ενάντια στα παθογόνα. Αυτό μπορεί να αποτελεί μια εξήγηση ως προς το γιατί οι ασθενείς με 
ΣΕȁ υποφέρουν από υποτροπιάζουσες λοιμώξεις. 
Ενώ τα μακροφάγα έχουν σημαντική αμυντική και καθαριστική λειτουργία, είναι και οι 
κύριοι ένοχοι της φλεγμονής που οδηγεί στην ανάπτυξη και την μετάσταση του καρκίνου. 
Στη δεύτερη μελέτη, ανακαλύψαμε ότι ορισμένα μακροφάγα, στον καρκίνο του μαστού και 
του παχέος εντέρου, καθώς και του μελανώματος (καρκίνου του δέρματος), εκφράζουν τον 
υποδοχέα MARCO. Έτσι, χρησιμοποιήθηκαν τα ίδια αντισώματα όπως και στην 
προηγούμενη μελέτη για την στόχευση του MARCO σε μακροφάγα εντός του όγκου, ώστε 
να ενεργοποιήθουν κατά αυτού. Τα αντισώματα στοχεύουν έναν υποπληθυσμό μακροφάγων 
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στο καρκινικό περιβάλλον. Σειριακές θεραπείες με αντισώματα κατά του MARCO, καθώς 
επίσης και με αντισώματα που ενεργοποιούν άλλα κύτταρα του ανοσοποιητικού, οδηγούν 
στην επανεκπαίδευση των μακροφάγων. Έτσι επάγουν την παραγωγή μορίων τα οποία 
ενεργοποιούν άλλα κύτταρα του ανοσοποιητικού έναντι του όγκου, αντί να τα 
καταστέλλουν. Αυτό οδηγεί σε σημαντικά μικρότερη ανάπτυξη και μετάσταση του 
καρκίνου. Η παρουσία του MARCO συνδέεται με τις πιο επιθετικές μορφές καρκίνου του 
μαστού και του μελανώματος, οι οποίες προκαλούν μετάσταση. Αυτή η μελέτη αποδεικνύει 
ότι ο υποδοχέας MARCO είναι ένας νέος μοριακός στόχος, σε τρεις διαφορετικούς τύπους 
καρκίνου και ότι τα αντισώματα μπορούν να χρησιμοποιηθούν ως εργαλεία για την ειδική 
στόχευση MARCO-μακροφάγων στον καρκίνο. Ως εκ τούτου, η προκείμενη στρατιγική 
στόχευσης μπορεί μελλοντικά να αποτελέσει μια χρήσιμη θεραπεία κατά του καρκίνου. 
Τα καρκινικά κύτταρα μπορούν να αναπτυχθούν σε τοπικό επίπεδο ή να ταξιδέψουν μέσω 
του αίματος και του λεμφικού συστήματος σε απόμακρα σημεία του σώματος όπου 
δημιουργούν μεταστάσεις. Τα μεταστατικά καρκινικά κύτταρα, έχουν ενεργοποιήσει ένα 
συγκεκριμένο γονιδιακό πρόγραμμα προκειμένου να αποκτήσουν την ικανότητα να 
μεταναστεύσουν. Το συγκεκριμένο γονιδιακό πρόγραμμα ενεργοποιείται υπό κανονικές 
συνθήκες κατά τη διάρκεια της εμβρυϊκής ανάπτυξης, όταν τα κύτταρα ταξιδεύουν σε 
διαφορετικές τοποθεσίες του αναπτυσσόμενου εμβρύου, προκειμένου να σχηματίσουν 
διάφορα όργανα, και είναι γνωστό ως επιθηλιακή-μεσεγχυματική μετάβαση (ΕȂȂ). Η 
λανθασμένη ενεργοποίηση του EMȂ αποδίδεται στην παραγωγή του μορίου-σηματοδότη 
ΤGF-β από τα καρκινικά και από άλλα χειραγωγημένα κύτταρα του ανοσοποιητικού, όπως 
τα μακροφάγα στο καρκινικό μικροπεριβάλλον. Στην Τρίτη μελέτη, ερευνούμε την επίδραση 
του ΤGF-β στα κύτταρα του καρκίνου του μαστού. Πράγματι, τα καρκινικά κύτταρα που 
αναπτύχθηκαν μόνο σε τοπικό επίπεδο, άλλαξαν μορφολογία και απέκτησαν 
μεταναστευτικές ικανότητες λόγω του ΤGF-β. Επίσης, ενστερνίζονται χαρακτιριστικά ενός 
άλλου τύπου κυττάρων του ανοσοποιητικού, των δενδριτικών κυττάρων, πρωταρχικός ρόλος 
των οποίων είναι η ανάλυψη παθογόνων και η μετακίνηση μέσω του λεμφικού συστήματος 
σε κομβικά σημεία του ανοσοποιητικού, όπου παρουσιάζουν τα παθογόνα και να 
ενεργοποιούν ειδικές ανοσοαποκρίσεις. Ȃε παρόμοιο τρόπο, ο ΤGF-β οδηγήσει στην είσοδο 
των καρκινικών κυττάρων στο λεμφικό σύστημα, δίνοντάς τους πρόσβαση σε απόμακρες 
τοποθεσίες του σώματος όπου μπορούν να συνεισφέρουν στη δημιουργία νέων όγκων.  
Τα εξωσώματα είναι μικρά κυστίδια που απελευθερώνονται από πολλούς διαφορετικούς 
τύπους κυττάρων στο σώμα μας. Δρουν ως μέσο επικοινωνίας, μεταφέροντας μοριακά 
μηνυμάτα μεταξύ κυττάρων. ȁόγω αυτού, μπορούν να χρησιμοποιηθούν για την φόρτωση 
μορίων τα οποία στοχεύoυν συγκεκριμένα κύτταρα του ανοσοποιητικού και  διαφορετικού 
τύπου ανοσοποιητικές αποκρίσεις. Στη μελέτη IV, χρησιμοποιήσαμε εξωσώματα από 
δενδριτικά κύτταρα, τα οποία είναι γνωστό ότι παρουσιάζουν ξένα μόρια για την 
ενεργοποίηση ανοσοαντιδράσεων. Αυτά φορτώθηκαν με α-GalCer, ένα λιπίδιο που αποτελεί 
ενεργοποιητή ενός τύπου ανοσοκυττάρων, γνωστά ως ȃȀΤ κύτταρα. Ο εμβολιασμός 
πειραματοζώων χρησιμοποιώντας εξωσώματα φορτωμένα με α-GalCer οδηγεί σε μια πιο 
αποτελεσματική ενεργοποίηση των ȃȀΤ κυττάρων, καθώς επίσης και άλλων κυττάρων του 
ανοσοποιητικού συστήματος, από ό, τι  θα προκαλούσε απομονωμένα το α-GalCer. Αυτό 
αποτελεί ιδιαίτερα σημαντικό εύρημα όσον αφορά τον καρκίνο, καθώς εξωσώματα 
φορτωμένα με α-GalCer μαζί με κάποιο μόριο που εκφράζεται από τον καρκινικό όγκο, 
ενεργοποίησαν κύτταρα του ανοσοποιητικού συστήματος εναντίον του καρκίνου 
περιορίζοντας την ανάπτυξή του. 
Εν κατακλέδι, η συγκεκριμένη διατριβή προσδιορίζει νέους στόχους στο μικροπεριβάλλον 
του καρκίνου, οι οποίοι μπορούν να χρησιμοποιηθούν για τη βελτίωση του σχεδιασμού 
μελλοντικών θεραπειών, προς όφελος των ασθενών με καρκίνο. 
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